1	Title Revend Volumet Unreveling the Consting of Human Prain Cosmetry
2 3	Beyond volume: Unraveling the Genetics of Human Brain Geometry
4	Authors
5 6	Sabrina A. Primus ^{1,2,3} , Felix Hoffstaedter ^{4,5} , Federico Raimondo ^{4,5} , Simon B. Eickhoff ^{4,5} , Juliane Winkelmann ^{1,3,6,7} , Konrad Oexle ^{1,2,3,†,*} , Kaustubh R. Patil ^{4,5,†,*}
7 8 9	Email of corresponding authors: konrad.oexle@helmholtz-munich.de, k.patil@fz-juelich.de
10 11	
12	Affiliations
13	
14 15	1 Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
16	2 Neurogenetic Systems Analysis Group, Institute of Neurogenomics, Helmholtz Zentrum
17	München, German Research Center for Environmental Health, Neuherberg, Germany.
18	3 Institute of Human Genetics, IUM School of Medicine and Health, Technical University of Munich, Munich, Germany
20	4 Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), Research Centre
21	Jülich, Jülich, Germany.
22	5 Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University
23	Düsseldorf, Düsseldorf, Germany.
24 25	6 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 7 German Center for Mental Health (DZPG), partner site Munich, Augsburg, Munich
26	Augsburg, Germany.
27	
28	[†] These authors contributed equally to this work.
29 20	
30 31	Abstract
20	
32 33	Laplace-Beltrami operator's spectrum of eigenvalues (LBS). We examined LBS genetics of 22
34	subcortical brain structures including cerebellum in 19.862 healthy White-British UK Biobank
35	participants by multivariate GWAS (MOSTest) on the first 49 eigenvalues each. Controlling for
36	surface and volume, we identified 80 unique variants (p<1/22*5E-8) influencing the shapes of
37	one or several structures, with the highest yield (37 variants) for brain stem. The previously
38	known influence of several of these loci on basic morphology, such as volume, is thus shown to
39 40	neurodegeneration alcohol consumption and mental disorders hint at preclinical stages of these
41	conditions potentially mediating the genetic effect on brain morphology. Significant correlations
42	between LBS of several brain structures and the polygenic risks of hypertension, ischemic stroke
43	and schizophrenia evince brain shapes as early biomarkers.
44	Teason
45 46	I easer Multivariate association study reveals genetic basis of detailed brain shape beyond volume.
47	and possible relations to neurodegenerative diseases.
48	
49	

50 MAIN TEXT

51

52 Introduction

The human brain comprises an intricate constellation of diverse substructures, each of which has specific functions and forms complex interactions with other parts of the brain. Investigating the morphological properties of these substructures and deciphering their genetic underpinnings is imperative for advancing our understanding of the human brain in health and disease. Previous genetic studies have investigated crude parameters such as volume and surface area (1-5) The genetics of the intricate shapes of brain structures remain largely unexamined, however, representing a gap in comprehensive understanding of brain anatomy.

The structures within the human brain exhibit a range of shapes, from the more spherical 60 amygdala to the elongated hippocampus. Basic metrics such as volume and surface area do not 61 adequately capture the nuanced details of these shapes and thus fall short of providing a sufficient 62 description of their morphology. There is evidence for a high inter-individual variance in these 63 intricate details, with a substantial proportion being heritable (6-8). Initial efforts to delve into the 64 genetic underpinning of this heritable aspect used techniques like voxel-based analysis in 65 combination with dimension reduction methods (9, 10), or global-to-local representations of brain 66 shapes (11, 12). Each of these techniques carries its own challenges, including reduced robustness 67 and accuracy due to suboptimal image registration, high computational effort, or a lack of 68 physical interpretability due to dimensionality reduction or a prohibitive dimensionality of image-69 70 derived features.

The Laplace-Beltrami operator provides a multivariate spectral representation of a shape, 71 capturing its characteristics in detail (13, 14). The Laplace-Beltrami spectrum (LBS), a set of 72 ordered eigenvalues, is obtained by solving the Helmholtz equation, a time-independent form of 73 the wave equation, on a Riemannian manifold which can be the surface of a given brain structure. 74 Solutions are decomposed into eigenfunctions (also referred to as "eigenmodes") and their 75 corresponding eigenvalues representing the natural vibrations and their squared frequencies, 76 respectively, on the manifold underlying the shape, akin to the harmonic frequencies of the 77 78 membrane of a drum. Each sound or other vibration of a membrane can be represented as a weighted sum of its eigenmodes, relating closely to the theory of spectral analysis in Fourier 79 80 series. Necessarily, the eigenmodes are strongly linked to a shape's geometry, as visualized in a 81 seminal experiment by Ernst Chladni using vibrating plates (15). It has been asked since then whether a shape can be represented by a unique series of eigenvalues or, metaphorically, whether 82 the shape of a drum can be heard (16). While the answer is affirmative for one-dimensional 83 84 shapes whose lengths are made audible by the harmonics or pure tones of string instruments, for instance, this is not true in general for shapes with more than one dimension as there exist 85 isospectral shapes (17). Nevertheless, the known counterexamples appear to be rare (13) and 86 87 under certain symmetry assumptions, a unique assignment is possible (18). Consequentially, a 88 relatively small subsequence (e.g. 50 eigenvalues) of the increasingly ordered spectrum contains enough geometric information to uniquely describe a shape by adequately capturing its curvatures 89 90 (13, 19–21), although the spectrum usually contains an infinite number of eigenvalues. Following 91 Ge et al. (6), we refer to this subsequence as the LBS (also known as Shape-DNA (13)). This multidimensional intrinsic shape representation, as an isometric invariant, is independent of 92 rotation, translation, and scaling of the coordinate system, eliminating the need for error-prone 93 94 inter-individual image registration (22), and behaves continuously with any change in the manifold. Recently, there is considerable interest in using geometric eigenmodes to explain 95 shape-associated biological mechanisms (23). The LBS appears to be a more straightforward 96 shape descriptor, however, which is computed efficiently (21) and thus well suited for large-scale 97

98 genome-wide association studies (GWASs) which require a quantitative representation of the 99 shape of brain structures at the individual level.

By performing GWAS, we aimed to reveal information on gene loci contributing to the 100 heritability of brain morphology as quantified by LBS. We derived the LBSs of 22 different brain 101 structures from a large MRI dataset provided by the UK Biobank (UKB). To reveal shape-specific 102 103 signals, we controlled for global characteristics such as brain volume and surface area. Since all eigenvalues in an LBS contribute to the description of the respective shape, it is important to 104 study them jointly while accounting for their mutual dependencies. To achieve this, we employed 105 the state-of-the-art multivariate GWAS tool MOSTest (2), which accounts for the pairwise 106 correlations between eigenvalues and, by considering their joint distribution, has increased power 107 for detecting genetic associations. Our study focused on subcortical structures, brain stem and 108 cerebellum, in keeping with several studies which studied the genetics of their volumes (2, 5, 24-109 26). These parts of the brain are not only involved in learning and decision-making processes (27) 110 but also hotspots of various brain disorders (7, 24-26, 28). We identified specific genetic 111 influences on their shapes, investigated genetic asymmetries and similarities among structures, 112 obtained precise estimates of the heritability of these shapes, and performed genetic correlation 113 and enrichment analyses with respect to biological pathways, traits, and diseases. 114

116 **Results**

115

117

118 Multivariate Genome-wide Analyses

MOSTest on the LBS of each of the 22 brain structures in 19,862 healthy, unrelated, 119 White-British individuals (10.427 female, with mean age+SD of 64.3+7.4 years) yielded a total 120 of 148 significant SNPs (Bonferroni-corrected for multiple testing p < 1/22 * 5E-8 = 2.27E-9) 121 which were each independent (linkage disequilibrium (LD) of $r^2 < 0.6$) in their respective LBS 122 GWAS. Some of them were significant in multiple brain structures. Thus, across all 22 GWASs, 123 124 there were 80 unique SNPs independently associated with the shape of at least one brain structure (Table S1, Fig. S1-S3). Using FUMA (29) for clumping the results of each brain structure (see 125 Methods), we identified 62 genomic risk loci in total, of which 48 were shared by at least 2 of the 126 22 brain structures (Fig. 1). The largest number of independent significant SNPs were found for 127 128 brain stem (37) (Fig. 2B), followed by left cerebellum white matter (29). Only the amygdala did not show any significant signals after Bonferroni correction. The strongest signal was observed 129 for lead SNP rs13107325 on chromosome 4 with a p-value of 2.15E-74 in association with the 130 LBS of the left cerebellum white matter. This SNP association was observed most frequently, 131 appearing in 14 of the 22 brain structures. 132

49 of the 80 independent SNPs, either themselves or via a proxy variant ($r2 \ge 0.6$), have previously been identified in GWASs on brain shape-related traits (e.g., volume, surface area, or cortical thickness) and are listed in the GWAS catalog implemented in FUMA. Of these 80, 13 have been associated exclusively with other traits (not brain shape-related), and 18 were not related to any GWAS catalog entry (Table S1).

- 138
- 139



Fig. 1. Overview of Genomic Risk Loci in Different Brain Structures. A: Anatomical representation of the subcortical brain structures assessed in the present study. B: Circular plot indicating the genomic risk loci derived by MOSTest GWAS on each brain structure. Bilateral structures are on neighboring circles and are the same color as in A, with the right-side structure represented more centrally and lighter. If multiple structures share a locus, the bars indicating their position on the respective circles are the same color.

140

141 Functional Annotations of Genomic Risk Loci

We annotated our results using ANNOVAR (30) as implemented in FUMA. Of the 80 142 independent significant SNPs, 3 were exonic, 27 were intronic, and 33 were in intergenic regions 143 (Fig. 2A, Table S2). All 3 exonic variants (rs13107325, rs1687225, rs601558) were 144 nonsynonymous, each having a combined annotation-dependent depletion (CADD) score higher 145 than 15.23 and belong, therefore, to the 3% most deleterious SNPs (31). We further found 28 146 exonic nonsynonymous (ExNS) variants in LD ($r2 \ge 0.6$) with one of the independent significant 147 SNPs, with 17 of them having a CADD score higher than 15.23 or a Regulome DB score (RDB; 148 small scores indicating a high likelihood of being a regulatory SNP) lower than 2 (Table 1, Table 149 150 S3).





The pleiotropic missense variant rs13107325, as mentioned above, affects the metal transporter *SLC39A8* and is, with a CADD score higher than 20 (23.1), among the 1% most deleterious SNPs. While ClinVar (*32*) and AlphaMissense (*33*) classify this pleiotropic variant as benign, it is a well-known risk factor for schizophrenia (*34–36*) and has also been found in conjunction with inflammation-based diseases like Crohn's disease (*37*), blood pressure (*38*) as well as brain imaging phenotypes (*9*).

VWA5B2 on chromosome 3 comprises the ExNS missense variant rs1687225, an
 independent significant SNP associated with brain stem LBS (p=5.6E-10). The CADD score of
 this variant is relatively high (19), but this SNP is not reported in ClinVar and AlphaMissense
 predicts it to be likely benign. Of note, the variant is a brain expression quantitative trait locus
 (eQTL) for different genes and an independent brain cis-eQTL for *VWA5B2* itself according to
 GTEx (v.8) (Table S4).

The ExNS missense variant rs601558 on chromosome 8 was significantly associated with the LBS of the left cerebellum cortex (p=8.0E-11) and is contained in *RSPO2*, for which it is also a brain eQTL. Despite a high CADD score of 22, this variant is classified as benign by ClinVar and AlphaMissense.

Despite its benign classification by ClinVar and AlphaMissense, rs17651549 in MAPT on 167 chromosome 17, which was associated with the brain stem LBS at p=1.0E-13, had the highest 168 CADD score (26.8) among the ExNS variants. It was in nearly complete LD ($r_2=0.96$) with the 169 lead SNP rs568589031 (brain stem, p=2.4E-16) of this large genomic risk locus that included 170 altogether 6 ExNS SNPs which, according to CADD score, all belong to the 3% most deleterious 171 SNPs (Table 1) and act as brain eQTLs of CRHR1, SPPL2C, MAPT and KANSL1. Due to its high 172 173 linkage, this large genomic region, also referred to as MAPT locus, is known to be highly complex (39) and we observed 18 ExNS SNPs being brain eQTLs of 17 protein-coding genes in total 174 (Table S5). 175

1	70	
1	/0	

rsID	Position	EA	NEA	EAF	MinP	CADD	RDB	Gene	Brain Structure (IndSigSNP, r2)
rs1687225	chr3:183948663	А	G	0.23	6E-10	19.0	4	VWA5B2	Brain Stem (<i>rs1687225</i> , 1.00)
rs902417	chr3:183951431	Т	С	0.25	7E-08	15.4	5	VWA5B2	Brain Stem (<i>rs1687225</i> , 0.86)
rs3733197	chr4:102839287	А	G	0.35	2E-06	14.2	7	BANK1	Left Cerebellum White Matter (<i>rs114614648</i> , 0.72)
rs13107325	chr4:103188709	т	С	0.08	2E-74	23.1	5	SLC39A8	Accumbens area (right + left: rs13107325 , 1.00); Cerebellum Cortex (right + left: rs13107325 , 1.00); Cerebellum White Matter (right + left: rs13107325 , 1.00); Pallidum (right + left: rs13107325 , 1.00); Putamen (right + left: rs13107325 , 1.00); Ventral DC (right + left: rs13107325 , 1.00); Thalamus Proper (right: rs13107325 , 1.00; left: rs13135092 , 0.93)
rs7800072	chr7:84628989	G	т	0.32	3E-08	18.3	5	SEMA3D	Brain Stem (<i>rs10247311</i> , 0.90)
rs601558	chr8:108970367	G	А	0.34	8E-11	22.0	5	RSPO2	Left Cerebellum Cortex (<i>rs601558</i> , 1.00)
rs36045050	chr14:69257858	т	с	0.26	8E-09	7.0	2b	ZFP36L1	Cerebellum White Matter (right: rs1547050 , 0.74; left: rs12435718 , 0.73)

rs4646626	chr15:58256127	т	с	0.46	6E-15	19.7	NA	ALDH1A2	Brain Stem (<i>rs1061278</i> , 0.91); Cerebellum Cortex (right: <i>rs3742960</i> , 0.92; left: <i>rs3742959</i> , 0.92)
rs1877031	chr17:37814080	А	G	0.33	1E-06	23.1	NA	STARD3	Brain Stem (<i>rs2271308</i> , 0.80)
rs1058808	chr17:37884037	G	С	0.33	1E-07	23.5	5	ERBB2	Brain Stem (<i>rs2271308</i> , 0.64)
rs12949256	chr17:43507297	Т	С	0.19	1E-08	15.0	4	ARHGAP27	Brain Stem (<i>rs568589031</i> , 0.70)
rs16940674	chr17:43910507	Т	С	0.24	1E-13	17.6	1f	CRHR1	Brain Stem (<i>rs568589031</i> , 0.96)
rs16940681	chr17:43912159	С	G	0.24	1E-13	5.0	4	CRHR1	Brain Stem (<i>rs568589031</i> , 0.96)
rs62621252	chr17:43922942	С	т	0.24	6E-14	6.3	5	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.96)
rs62054815	chr17:43923266	А	G	0.24	1E-13	0.0	5	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.96)
rs12185233	chr17:43923654	С	G	0.24	5E-14	23.5	1f	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.95)
rs12185268	chr17:43923683	G	А	0.24	1E-13	8.7	1f	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.96)
rs12373123	chr17:43924073	С	Т	0.24	1E-13	23.3	1f	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.96)
rs12373139	chr17:43924130	А	G	0.24	1E-13	4.0	1f	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.96)
rs12373142	chr17:43924200	G	С	0.24	7E-13	7.5	1f	SPPL2C	Brain Stem (<i>rs568589031</i> , 0.96)
rs63750417	chr17:44060775	т	С	0.24	1E-13	11.9	5	MAPT	Brain Stem (<i>rs568589031</i> , 0.96)
rs62063786	chr17:44061023	А	G	0.24	9E-14	7.9	5	MAPT	Brain Stem (<i>rs568589031</i> , 0.96)
rs62063787	chr17:44061036	С	Т	0.24	1E-13	0.2	5	MAPT	Brain Stem (<i>rs568589031</i> , 0.96)
rs17651549	chr17:44061278	Т	С	0.24	1E-13	26.8	1f	MAPT	Brain Stem (<i>rs568589031</i> , 0.96)
rs10445337	chr17:44067400	С	Т	0.24	2E-13	19.2	1f	MAPT	Brain Stem (<i>rs568589031</i> , 0.96)
rs62063857	chr17:44076665	G	А	0.24	1E-13	1.5	7	STH	Brain Stem (<i>rs568589031</i> , 0.96)
rs34579536	chr17:44108906	G	А	0.24	2E-13	14.4	3a	KANSL1	Brain Stem (<i>rs568589031</i> , 0.96)
rs34043286	chr17:44117119	G	А	0.24	1E-13	21.0	4	KANSL1	Brain Stem (<i>rs568589031</i> , 0.96)

Table 1. Exonic Nonsynonymous Variants in LD ($r2 \ge 0.6$) with one of the Independent Significant SNPs Across all Brain Structures. Variants are listed with non-effect allele (NEA), effect allele (EA), and effect allele frequency (EAF), minimal significance level (minP) across all structures, CADD and RDB scores, most likely affected gene, and the independent significant SNPs (IndSigSNP) to which they are linked most strongly as indicated by the correlation value r2. The respective IndSigSNP may differ between brain structures according to the structure-specific GWAS results. Blue-marked variants have CADD > 15.23 or RDB < 2. Bold typing of a variant indicates genome-wide significance in at least one brain structure. Variants in italics are independent significant SNPs.

177

178Asymmetry and Similarity of Brain

179 Structures

180 To assess possible genetic asymmetries and similarities of brain 181 182 structures, we compared the p-values of the 80 unique independent SNPs between 183 184 structures and hemispheres (Table S6). Applying a conservative Bonferroni 185 correction for 80*22 comparisons to the 186 nominal threshold of 0.05, we found five 187 genome-wide significant (p < 2.27E-9) 188 SNPs for cerebellum white matter and 189 190 one for putamen that were not significant in the respective contralateral structures. 191 At nominal significance, only the intron 192 variant rs2845878 in FAT3, which came 193





- up in the GWAS on right putamen, lacked symmetry. Proxy variants of rs2845878 ($r2 \ge 0.6$) have been linked to the mean volume of caudate and putamen according to GWAS catalog (4).
- Principal component (PC) analysis of -log10 transformed p-values of these 80 SNPs showed a
- 197 high level of symmetry and similarity in genetic signals (Fig. 3): All subcortical structures as well
- as the cerebellum cortex were mapped close to each other in this PC space, independent of their
- 199 hemispherical assignment. Moreover, most structures shared genetic architecture according to
- 200 their placement adjacent to each other as in case of the basal ganglia, for instance. However, brain
- stem, cerebellum white matter and hippocampus were substantially distanced from the others in at
- least one of the first three PCs. Hippocampus was probably notable for its dissimilar pattern of
 few associated SNPs while the particular position of brain stem and cerebellum white matter
- 204 could be due to their highly significant signals in addition to their quantity.

When investigating genetics that were similar for several structures, the ExNS variant 205 206 rs13107325 in SLC39A8 along with several others within the same risk locus on chromosome 4, the intergenic SNP rs6658111 on chromosome 1 and the intronic variant rs12146713 in NUAK1 207 on chromosome 12 emerged as the most frequently shared independent SNPs. After Bonferroni 208 209 correction for 80*22 comparisons, these three were significant in 10 to 15 structures and nominally significant in 19, respectively, 20 structures (Table S6). Apart from the pleiotropic 210 rs13107325, the other two variants have so far only been linked to various brain shape traits such 211 as volume, surface area and cortical thickness according to the GWAS catalog (Table S7). 212 Interestingly, rs12146713 and rs13107325 have also recently been linked to structural 213 connectivity measures (40) which supports the notion that they have an overarching effect on 214 215 brain structuring.

216

217 Gene-mapping and Gene-enrichment Analysis

We first annotated all SNPs passing QC to 18383 protein-coding genes using MAGMA 218 219 (41) and calculated a p-value for each gene by applying the SNP-wise mean model (see Methods). 220 The brain stem stood out with 20 protein-coding genes being significantly associated with its shape in the gene-based analysis after Bonferroni correction for 22 brain structures and 18383 221 222 protein-coding genes (p < 0.05 / (22*18383)) (Fig. 4A). Here, *CRHR1* showed the strongest signal (p= 5.2E-15). This gene belongs to the extended *MAPT* locus mentioned above, which 223 came up as generally highly significant and has, together with MAPT, which encodes for the 224 microtubule-associated protein tau, often been associated with neurodegenerative disorders (42, 225 226 43).

Next, we used PoPS (44) for gene prioritization, a tool that assigns polygenic priority scores to each gene by fitting their MAGMA z-scores based on trait-relevant gene features extracted from cell-type-specific gene expressions, biological pathways, and protein-protein interactions. Since PoPS works best when combined with orthogonal methods, we also mapped each SNP to the nearest genes. Reranking the genes according to the mean of the two ranks that resulted from the two methods, we prioritized all genes with rank ≤ 2 at each locus (see Methods, Table S8).

Based on these genes, a gene set enrichment analysis was conducted using FUMA's Gene2Func method. For bilateral brain structures the two gene sets were joined in this analysis due to similar genetic architectures on both sides (see above and Fig. 3). Afterwards, the overlap and degree of overrepresentation of all prioritized genes in predefined gene sets were examined.

At the locus of the most significant SNP in this study, rs13107325, two genes were usually prioritized, *BANK1* and *SLC39A8* (Table S8). The previously known pleiotropy of this genomic region was confirmed by the diversity of our enrichment results which included adventurousness, hypertension, multisite chronic pain, general cognitive ability, and alcohol consumption (Fig. 5A,

Fig. S4-S5 for all other structures). Especially the overlap with alcohol consumption was most prominent.

These two genes and 23 others were prioritized for the cerebellum white matter. However, given this entire set of genes, *BANK1* and *SLC39A8* were not significantly overrepresented in any gene set. Instead, the other genes, which were primarily prioritized by the cerebellar white matter, were enriched in several regulatory pathways associated with neurological and developmental processes (Fig. 5B).

For brain stem, Gene2Func identified gene sets linked to brain morphology and lung function according to GWAS catalog (Fig. 5C) as well as multiple biological processes from the



Fig. 4. Gene Analysis and Enrichment in Brain Stem. A: Manhattan plot of MAGMA gene analysis of brain stem results using SNP-wise mean model. **B:** Hypergeometric tests of overrepresentation and overlap of prioritized genes with predefined gene sets using FUMA Gene2Func. Overlap with gene sets of GO biological processes (MsigDB c5). P-values were corrected by the Benjamini-Hochberg method for multiple testing.



Fig. 5. Significant Gene Enrichment Results of Selected Brain Structures. Hypergeometric tests of overrepresentation and overlap of prioritized genes with predefined gene sets from GWAS catalog traits (**A**, **C**, **D**) and GO biological processes (**B**). Pallidum (**A**) was chosen as a representative for structures prioritizing *BANK1* and *SLC39A8* at the pleiotropic locus of rs13107325. All other structures can be found in the supplements. Cerebellum white matter (**B**), hippocampus (**C**) and brain stem (**D**) showed a substantially different genetic pattern before (Fig. 3). P-values were corrected by the Benjamini-Hochberg method for multiple tests in each category.

Gene Ontology Resource (GO) involved in cell and nervous system development and regulation
(Fig. 4B). Brain-stem-shape-related genes were additionally enriched in a set of genes
differentially expressed in early infancy brain tissue (Fig. S6).

Genes prioritized for hippocampus shape revealed a complete overlap with genes associated with its fissure, but only a partial overlap with its total volume (< 20%), reinforcing the validity and utility of our shape analysis (Fig. 5D).

257

258 Associations with Polygenic Risk Scores

To investigate associations between brain-related traits and the LBS of individual brain structures, we extracted polygenic risk scores (PRS) from UKB for Alzheimer's disease (AD), bipolar disorder (BD), ischemic stroke (ISS), multiple sclerosis (MS), Parkinson's disease (PD), and schizophrenia (SCZ). Due to results of our gene-set enrichment analyses (see above), we also included the PRS for alcohol use disorder (ALC) as available in the PGScatalog. 10 of the pairwise partial correlations (i.e. adjusted for covariates, see Methods) between the PRSs were significant (Bonferroni-corrected p < 0.05), most prominently between SCZ and BD (r = 0.37,

266 p < 1E-300), ALC and SCZ (r = 0.12, p = 1.5E-60), and ALC and BD (r = 0.09, p = 1.7E-38) 267 (Table S9-S11).

Following Sha et. al (45), we performed canonical correlation analysis (CCA) between the 268 LBS of each of the 22 brain structures and each of those PRSs (see Methods). Here, the CCA 269 determined a linear combination of the eigenvalues of an LBS (i.e. the canonical variable) which 270 correlates maximally with the PRS across all examined individuals. We found 31 significant 271 correlations after Benjamini-Hochberg (46) correction (p < 0.05) within each PRS, 11 of which 272 also stayed significant after additional Bonferroni correction for 6 independent PRSs (two-level 273 correction), and 6 survived an overall Bonferroni correction for 22*6 tests (Fig. 6). As a balance 274 between false discoveries and sensitivity, we chose this two-level correction to further investigate 275 associations between PRSs and brain structures. Significant correlations ranged from 0.065 to 276 0.080 (mean 0.070). While we found several highly significant correlations with various brain 277 structures for ISS and SCZ, the polygenetic risk for BD and PD did not correlate with any brain 278 shape at all. This is particularly notable since the PRS of BD and SCZ had substantial correlation 279 (see above). The PRSs of AD, ALC, and MS indicated only suggestive correlations with LBSs. 280

To interpret these findings at the level of the eigenvalues, we calculated the mean loadings 281 in each CCA and counted the number of negative and positive values. We noticed that in some 282 results it was possible to assess a common direction of effects. Among all significant results, the 283 right ventral diencephalon (DC) revealed the strongest (i.e. largest absolute) mean loading of -284 0.295 with 96% of all eigenvalues having a negative correlation with the canonical variable and, 285 286 in case of a common direction, by that with the PRS of SCZ. This finding suggested that a person may have a higher genetic risk for schizophrenia if the right ventral DC is shaped in such a way 287 that its eigenvalues (frequencies) are lower. This, for example, can be the case for a smoother 288 surface or a less curved shape. A similar deduction in case of brain stem suggested that a less 289



Fig. 6. P-values of CCA Results of Different PRS with Various Brain Structures. Bar charts show the $-log_{10}$ scaled p-values of the correlations between polygenic risk scores and LBS of different brain structures at different significance levels: Bonferroni-corrected for 22 brain structures and 6 independent PRS (red line), FDR-corrected within each PRS (black line), FDR-corrected within each PRS + Bonferroni-corrected for 6 independent PRS (blue line). Above significant p-values, the correlation value is stated. Bilateral structures are labeled once and the one in the left hemisphere is placed more left.

smooth or more curved shape shows a higher risk for ISS (mean loading 0.186 with ~92%
loadings positive).

Although most correlations remained above the significance threshold, clustering of the
 mean loadings showed similar tendencies for both hemispheres suggesting no asymmetric
 behavior (Fig. S7).

296 Heritability

295

297 We used SCORE (47) to estimate the univariate heritability of each eigenvalue which utilizes the individual genotype data similar to the analysis by Ge et al. (6). We also calculated the 298 multidimensional heritability (6) (see Methods) for each brain structure (Table 2, Table S12). 299 Overall, the multidimensional heritability of the LBS was significant for all examined brain 300 structures (Bonferroni corrected for 22 structures; range h^2 ; [9.5%, 29.6%], mean 17.2%). The 301 highest heritability was found for the caudate (left: 29.6% and right: 27.3%) as well as for the 302 brain stem (28.2%). We further computed the multidimensional LBS heritability for combined 303 304 structures to compare them with the results from Ge et al. (Table 2, Fig. S8) and found a positive linear correlation (Pearson's r = 0.735, p = 0.038). However, Spearman's rho did not reach 305 statistical significance (rho = 0.714, p = 0.058), suggesting a nonmonotonic relationship. 306 Excluding the 4th Ventricle, which may be an outlier in Ge et al. due to its large standard error and 307

Brain Structure	h^2	SE	h ²	SE	h ²	SE
4th Ventricle	0.169	3.0E-3	0.169	3.0E-03	0.005	0.208
Left Accumbens area	0.134	2 8F-3				
Right Accumbens area	0.095	2.4E-3	0.116	1.9E-3	0.237	0.135
	0.000	2.72.0				
Binkt Amundala	0.105	2.52-5	0.118	1.8E-3	-	-
Right Amygdala	0.134	2.8E-3				
Left Caudate	0.296	1.9E-3	0.285	1.4E-3	0.499	0.188
Right Caudate	0.273	2.0E-3				01100
Brain Stem	0.282	5.4E-3				
Left Cerebellum Cortex	0.186	2.9E-3				
Right Cerebellum Cortex	0.194	2.8E-3	0.198	1.5E-3	0.452	0.192
Left Cerebellum White Matter	0.195	2.6E-3				
Right Cerebellum White Matter	0.148	2.6E-3				
Left Hippocampus	0.187	2.6E-3	0 100	1052	0.247	0 160
Right Hippocampus	0.210	2.7E-3	0.155	1.92-5	0.547	0.103
Left Pallidum	0.124	2.9E-3	0 122	205.2	0.061	0 117
Right Pallidum	0.120	2.8E-3	0.122	2.02-5	0.001	0.117
Left Putamen	0.158	2.7E-3	0 192	1052	0 412	0 149
Right Putamen	0.210	2.8E-3	0.105	1.92-3	0.413	0.140
Left Thalamus Proper	0.134	2.7E-3	0 132	1 05 3	0.086	0 1/3
Right Thalamus Proper	0.130	2.7E-3	0.132	1.92-3	0.000	0.143
Left Ventral DC	0.122	2.7E-3	0 146	2 15 3		
Right Ventral DC	0.169	3.2E-3	0.140	2.12-3	-	-

Table 2. Heritability Estimates of Different Brain Structures. Heritability estimates are presented for single brain structures (h^2) and for combined regions $(h^2 \text{ combined})$ as well as their standard errors (SE and SE combined). Here, numbers in bold are significant after Bonferroni correction for 22 brain structures. For comparison, the estimates from Ge et al. are listed in the last two columns. Italic numbers are nominally significant and bold ones are significant after false discovery rate correction in (6).

very low heritability, both results affirm a significant correlation (r = 0.844, p = 0.017 and rho = 0.786, p = 0.048). We further conducted a Wald test for different heritability in each combined brain structure with H_0 : $h^2 = h_{Ge}^2$, which could not be rejected at a 0.05 significance threshold for any of the structures (see Methods and Table S13), implying that our heritability estimates do not differ significantly from those of Ge et al.

313

314 **Replication**

On the 20% replication sample (N=4961), we performed a replication analysis of the 80 315 independent SNPs (see Methods). For each brain structure, we only investigated those variants of 316 the 80 SNPs which had also shown Bonferroni-corrected genome-wide significance in the 317 respective discovery GWAS. We replicated 51.4% (76/148) of all significant associations of these 318 80 SNPs at a 0.05 significance level after FDR correction and 60.8% (90/148) at nominal 319 significance level (Table S14). Hence, using a similar replication sample size, our replication rate 320 was at least 33% larger than in van der Meer et al. (2) who introduced MOSTest in their study on 321 322 brain volumes. To assess what can be expected as replication rate, we split our discovery set into 4 sets that equaled the replication set in size and sex and age distribution and checked the 323 "replication rate" in these sets. We obtained rates between 66.2% and 80.4% at FDR-controlled 324 325 significance and between 68.2% and 82.4% at nominal significance (Table S15). In view of the fact that replication rates of GWASs usually are much lower than expected by power analysis 326 (48% observed vs 91% expected), even after correction for winners' curse (48% vs 54%) (48), 327 this simple simulation showed that our actual replication rate in a set of independent individuals 328 was in keeping with the size of that set. 329

330331

332 Discussion

Examining the complex relationship among brain morphology, genetics and neurological 333 disorders is crucial for unravelling the underlying causes and enhancing our understanding of the 334 anatomy of the human brain and diseases. The Laplace-Beltrami operator provides a useful 335 spectral representation for describing shape characteristics. Adequately describing curvatures and 336 being an informative topological fingerprint of the shape (19), the Laplace-Beltrami spectrum 337 (LBS) captures more information compared to global shape quantities such as surface area or 338 volume. Specifically, it captures local shape effects but still represents the whole form of an 339 object since the respective eigenmodes are defined everywhere on the structure. Furthermore, the 340 shape is described by a relatively small number of values, which simplifies data handling, and, in 341 contrast to other dimension reduction methods like principal component analysis, spatial 342 interpretability is still given. Also, it does not depend on error-prone interindividual image 343 registration which is required by other methods. Using the LBS thus allowed us to specifically 344 345 address the variation in shape independent of volume or surface area and to disentangle the genetics of morphology beyond those global properties. While the eigenmodes and their potential 346 to explain shape-associated biological mechanisms have been recently explored (23), the 347 eigenvalues were previously found to have considerable heritability in the case of subcortical 348 brain structures and cerebellum (6). However, neither the genetic architecture at SNP level of the 349 shape of brain structures nor possible relations to disease genetics have been investigated vet. 350 351 Using state-of-the-art GWAS and the LBS (a set of eigenvalues) as a multidimensional phenotype, we have dissected the genetics of the shape of 22 brain structures in 19,862 White-352 British individuals from the UK Biobank. 353

Overall, we identified 148 significant SNP associations that were independent in their respective GWAS. Since some SNPs were significantly associated with more than one brain

structure, this resulted in 80 unique significant SNPs being independent across the 22 GWASs. Most of them, particularly the most significant ones, were detected in association with structures in the posterior fossa (brain stem and cerebellum). In contrast, we found no significant signal for the LBS of the amygdala. Due to the simple almond-like shape, crude measures like volume and surface area might already capture amygdala's shape well enough (Supplements, Table S16). This could possibly explain the lack of genetic signal in our study since we controlled for both volume and surface area.

Of those 80 SNPs, 37 have previously been reported as genome-wide significant in a large 363 GWAS on subcortical volumes (2), while 4 were identified in a large GWAS meta-analysis on 364 total brain volume (1). This overlap with volume-associated SNPs suggests pleiotropic effects of 365 the respective gene loci, affecting both volume and shape characteristics independent of volume, 366 while it is unlikely that pure volume associations were picked since we controlled for volume. 367 Indeed, our hippocampus LBS GWAS, for instance, replicated 100% of all loci previously 368 associated with hippocampal fissure size (49), which obviously influences hippocampal shape, 369 while accounting for only 20% of the loci associated with total hippocampal volume (Fig. 5D). 370

371 31 of the 80 independent SNPs were not associated with any brain shape-related trait 372 according to GWAS catalog, neither by themselves nor by any variant in LD with them ($r2 \ge$ 373 0.6), and 18 were not listed at all (Table S1). This shows a substantial degree of novelty, that is, 374 undiscovered genetic effects specific to shape of brain structures and supports the notion of SNPs 375 affecting the development of form independent of growth.

Using a 15 times larger sample size, we were able to substantially refine the LBS SNP-376 heritability estimates of subcortical brain structures, including cerebellum, previously provided by 377 Ge et al. (6) (N=1320). While their estimates ranged from 0.005 to 0.5, some being non-378 significant due to large standard errors of 0.12 to 0.21, our estimates were between 0.1 and 0.3, all 379 being significant with much lower standard errors (≤ 0.005). In fact, statistical tests implied that 380 381 our heritability estimates did not differ significantly from those of Ge et al. This was likely due to the much larger standard errors of their estimates but may also be a consequence of the younger 382 age span in their cohort (18-35 years). Overall, we achieved results with higher statistical 383 significance corresponding to our larger sample size and also likely due to our additional control 384 for total brain volume, the respective local surface area, and MRI scan quality. The refined 385 estimates were approximately equal to the SNP-heritability of volumetric traits of subcortical 386 387 structures which Hibar et al. (3) derived from similar sample sizes, or even larger as in the case of caudate, hippocampus and putamen, for which they derived a SNP-heritability of about 0.11 with 388 95%-CI < 0.16 each, while we found values of 0.29, 0.20, and 0.18 respectively. 389

Bilateral structures showed similar genetic architecture of LBS (Fig. 3), which could be 390 expected due to their symmetry. Moreover, genetic architecture was also shared between 391 structures, as suggested by their adjacent positions, e.g. in the case of the basal ganglia. The two 392 noticeably frequently shared variants rs13107325 and rs12146713 on SLC39A8 and NUAK1, 393 394 respectively, seem to affect brain shape globally as they have recently been associated with the structural connectome (40). While SLC39A8, as a brain metal transporter, is involved in several 395 brain and neurodevelopmental traits (see below), NUAK1 is also known to regulate axon 396 397 branching by controlling mitochondrial distribution (50). The genetic associations of cerebellum and brain stem LBS were more different. Brain stem stood out due to a high number of specific 398 association signals. These included the exonic nonsynonymous (ExNS) variant rs1687225 in 399 400 *VWA5B2*, the gene of von Willebrand factor A domain containing protein 5B2. This missense variant belongs to the 3% most deleterious variants (according to CADD score) and was also an 401 independent brain cis-eQTL of VWA5B2 according to GTEx (v.8). Proxy variants of rs1687225 402

have been reported as being associated with brain morphology (2), cortical thickness (51), and educational achievement (52).

An extended genomic risk locus on chromosome 17 with lead SNP rs568589031 was also 405 rather specific for the brain stem. ExNS variant rs17651549 at this locus had the highest CADD 406 score (26.8) of all variants in LD with any of the independent significant SNPs. It affects MAPT 407 which was among the most significant signals in MAGMA gene-based analysis of the brain stem 408 LBS. However, this locus contains multiple protein-coding genes with several brain cis-eQTLs 409 affecting them and other genes in the region (Table S5). The analysis of this large locus is highly 410 challenging. The locus has previously been mapped to brain morphology (2) and several 411 412 neurodegenerative diseases such as progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease, and Alzheimer's disease (AD) (42, 43, 53–62). 413 Moreover, variations in cortical morphology have recently been linked to $APOE \varepsilon 4$ and MAPT in 414 young healthy adults (63). There is also evidence of brain stem deformations in early stages of 415 AD manifesting as variations in the midbrain (64), decreased locus coeruleus (part of the brain 416 417 stem) volume preceding neuronal loss (65), and neurofibrillary tangle-related neurodegeneration in the brain stem potentially causing neuropsychiatric symptoms (66). While patients with 418 diagnosed neurodegeneration were excluded from our study, the possibility remains that 419 preclinical stages might potentially mediate the genetic relation between shape and the MAPT 420 locus. However, neither gene enrichment analysis (Fig. 4 and 5) nor Canonical Correlation 421 Analysis (CCA, Fig. 6), as an enrichment analysis independent of candidate genes, did provide 422 423 evidence for a significant correlation between the genetics or phenotype of brain stem LBS and the genetics, respectively the PRS, of neurodegeneration such as AD. 424

At this locus, significant ExNS SNPs with high CADD scores were also found in 425 SPPL2C, KANSL1 and CRHR1, which showed the strongest signal in the MAGMA analysis 426 (Table 1, Fig. 4A). Loss-of-function variants of KANSL1 are known for causing autosomal-427 dominant Koolen-de-Vries syndrome (MIM #610443) which is characterized by intellectual 428 disability and structural brain abnormalities (67). SPPL2C is the gene of signal peptide peptidase-429 like 2C and has previously been highlighted in a GWAS on total brain volume due to a relatively 430 large number of ExNS (1). However, we controlled for volume in our GWAS of brain shape. A 431 recent study found that CRHR1, which encodes a receptor for the corticotropin-releasing hormone 432 CRH, moderates brain volume differences, possibly through its stress response function, which in 433 return mediates the relationship between urban environmental exposure and affective symptoms 434 (68). Especially, in the context of CRHR1, lower brain volume was observed in relation to 435 436 stronger affective symptoms and greater urban environment exposure. Variants of *CRHR1*, have further been associated with alcohol (69) and heavy alcohol consumption following stressful life 437 (70). Even light alcohol consumption has recently been related to changes in brain structure (71). 438 Indeed, genes associated with the LBS of several other brain structures were enriched in gene sets 439 associated with alcohol consumption (Fig. 5A, Fig. S4-S5). Thus, alcohol consumption may be a 440 potential mediator of their effect on brain shape. However, we would like to note that the 441 enrichment was driven by one locus. 442

That locus on chromosome 4 with lead SNP rs13107325, an ExNS variant of SLC39A8, 443 appeared not only to be significant in most brain structures (15 structures including the brain 444 stem, albeit with subthreshold significance) but also revealed the overall strongest signal across 445 all the GWASs in left cerebellum white matter. This locus, especially the lead SNP, has a 446 pleiotropic effect. Besides alcohol consumption (72), it has been linked to schizophrenia (SCZ) 447 (34–36), Crohn's disease (37), blood pressure and cardiovascular disease risk (38), and several 448 brain imaging phenotypes (9). The cerebellothalamic and cerebellar-basal ganglia connectivity 449 dysfunction hypothesis in individuals with SCZ is supported by the significant and prominent 450

occurrence of rs13107325 in precisely these regions (73, 74). SCZ is known to be associated with
abnormalities of subcortical brain structures (75–77). Clinical features of SCZ might be due to
aberration of dendritic spine density (78). A knock-in mouse model of rs13107325 points to an
increased risk of SCZ by regulating zinc transport and dendritic spine density and subtle effects
on cortical development due to this variant (79). A recent gene-mapping study concluded strong
evidence for pleiotropic genes associated with SCZ and brain structure with evidence of brain
variation causing SCZ (80).

SCZ shows substantial genetic correlation (0.68) with bipolar disorder (BD) (81) which 458 was also evident in the correlation (0.37) between their PRSs. However, BD seems to have less 459 relation to brain morphology. Madre et al. (82) investigated cortical morphology in individuals 460 with SCZ and BD and reported shared volume and thickness deficits while abnormalities of 461 geometry and curvature were specific to SCZ. Also, Stauffer et al. reported the association of 462 MRI metrics to be weaker with BD genetics than with SCZ genetics (80). Our results are in line 463 with these findings as CCA revealed correlation of the LBS of several brain structures only with 464 465 the SCZ-PRS while there was no correlation with BD-PRS (Fig. 6). This result suggests that LBS may therefore be sensitive to SCZ-specific brain shape variations and thus potentially helpful for 466 the differential diagnosis of psychosis. 467

CCA also revealed highly significant links between the LBS of multiple brain structures 468 and the PRS of ischemic stroke (ISS) in our healthy cohort (Fig. 6). In line with the high 469 correlation between ISS-PRS and hypertension (HT) PRS, CCA produced a very similar result for 470 the HT-PRS (Fig. S9). HT is associated with white matter hyperintensities and cognitive 471 dysfunction in elderly patients and is a major risk factor for ISS (83). A recent study showed that 472 morphological changes in the basal ganglia and thalamus already occurring in mid-life are 473 associated with blood pressure and, therefore, might be better markers of early HT than volume 474 aberrations (84). Our CCA results were especially significant in these brain regions, which in turn 475 support the suggestion of using brain morphology or shape as an early biomarker of HT. 476

Limitations of our study include the lack of effect sizes (beta values) in our multivariate 477 results, which impedes the use of conventional post-GWAS tools such as genetic correlation and 478 Mendelian randomization analyses. Instead, we explored the relationship to genetics of other 479 traits by performing CCA between LBSs and PRSs. This was limited by the predictive power of 480 each PRS. Furthermore, we cannot establish causal relationship between genetic variation in brain 481 morphology and a particular trait or disease. Restricting our study to healthy individuals may 482 additionally have yielded lower effect sizes and potentially false negative correlations when 483 performing disease-related analyses. A follow-up of our findings, therefore, provides avenues for 484 future research. 485

In summary, we have provided the first delineation of the genetic architecture of brain 486 shapes beyond global measurements such as volume and surface area by using the Laplace-487 488 Beltrami spectrum as a mathematical shape descriptor. In our multivariate GWAS on a large healthy cohort of the UK Biobank, we identified 80 unique independent SNPs with brain stem 489 showing a distinctly high number of specific association signals which included the MAPT locus 490 implicated in neurodegenerative diseases. The shapes of most brain structures were significantly 491 associated with the pleiotropic variant rs13107325, a known risk factor for schizophrenia. We 492 further identified significant correlations between brain shape and polygenic risk scores of 493 494 schizophrenia, hypertension and ischemic stroke, suggesting the potential use of the LBS as an early disease biomarker. As such, the LBS expands the set of tools for investigating brain shapes, 495 holding implications for early detection of a wide spectrum of traits and warrants further research 496 in disease-specific cohorts. 497

498 Materials and Methods

499

500 UKB Data and Sample Filtering

501

502 Data was retrieved from the official source of the <u>UK Biobank</u> (application number 41655) and 503 provided as a DataLad dataset, a research data management solution providing data versioning,

504 data transport, and provenance capture (85). A total of 487,409 genotyped samples were available

- 505 (v3 imputed on Haplotype Reference Consortium and UK10K haplotype data, aligned to the +
- strand of the reference and GRCh37 coordinates, released in 2018, data field 22828). We kept
- only self-reported White-British individuals for data homogeneity according to data field 21000,
- resulting in 430,560 individuals. After genetic quality control (QC, see below), there were
- 393,913 unrelated samples left. 30,080 of them had structural MRI data (T1) on which we
- calculated the LBS (see below) of 22 brain structures (Fig. 1) of 24,834 individuals without
- 511 mental or behavioral disorders (ICD index F) or diseases of the nervous system (ICD index G)
- according to the International Statistical Classification of Diseases and Related Health Problems
 10th revision (ICD-10).
- 514 We created age and sex-stratified discovery and replication samples by splitting the data into 2
- subsets comprising 80% and 20% of the individuals, respectively. Excluding samples without
- total brain volume data (see below), our final data set for our discovery GWAS contained 19,862
- individuals, 9435 male and 10,427 female, ranging in age between 46.0 and 81.7 years with a
- 518 mean \pm SD of 64.3 \pm 7.4 years (female: 63.6 \pm 7.3, male: 65.0 \pm 7.5).
- 519

520 Quality Control of Genetic Data

521

We conducted OC using whenever possible Plink2 (86) and Plink (v1.9) for some missing 522 functionalities on all self-reported White-British individuals and their imputed genotype data, 523 which was initially converted from BGEN to binary Plink2 format, and kept only single-524 nucleotide polymorphisms (SNPs). As recommended by UK Biobank (87), we removed variants 525 with an imputation score less than 0.3, and following Mills et al. (88), we excluded all variants 526 with a call rate less than 0.95, a minor allele frequency of less than 0.01 and a Hardy-Weinberg 527 equilibrium exact test p-value below 1E-6. As recommended by Plink2, we used the mid-p 528 adjustment to reduce the filter's tendency to retain variants with missing data (89) and the keep-529 fewhet modifier. We also removed samples with a mismatch between self-reported and 530 genetically inferred sex, with genotype missingness of more than 0.05, and all heterozygosity 531 outliers (+3 SD). Moreover, using a kinship coefficient of 0.088 and the king-cutoff command, 532 we randomly excluded one from each pair of individuals related to \geq 2nd degree. Only autosomal 533 SNPs were examined. In total 8,105,763 SNPs remained after QC. We calculated the first 10 534 principal components (PC) from them, which were included as covariates in the GWASs. 535

536

537 Image Data Processing

538

539 First, we segmented anatomical structures from all available T1 MRI brain scans with FreeSurfer 540 version 7.2.0 (90–94). Second, we created triangular meshes for all structures of interest. Finally, 541 we computed compact shape representations for all structures, using the BrainPrint Python 542 package (21) (see below). To account for the quality of the MRI scans, we computed the Euler 543 number with FreeSurfer. This represents the total defect index and is a measurement of the 544 number of holes in the calculated surface.

545 546

547 548

7 Multidimensional Shape Descriptor

A shape, parametrized as a Riemannian manifold *M*, may be described by its intrinsic geometric information, which can be obtained by solving the Helmholtz equation on that manifold:

- 551 552
- 553

 $\Delta f = -\lambda f,$

where Δ is the Laplace-Beltrami operator, a generalization of the Laplace operator in Euclidean space, and f a real-valued function, with $f \in C^2$, defined on M. The solutions (f_i, λ_i) represent the spatial part of the wave equation with eigenfunctions f_i and eigenvalues λ_i where $\sqrt{\lambda_i}$ can be interpreted as the natural frequencies. The set of all eigenvalues is called the spectrum of an operator. The LBS or Shape-DNA (13) is accordingly defined as the beginning subsequence of the increasingly ordered spectrum of the Laplace-Beltrami operator solved on a Riemannian manifold:

- 561
- 562 563

 $\{\lambda_1, \dots, \lambda_N\}$ with $0 \le \lambda_i \le \lambda_j \quad \forall i < j$.

The LBS was computed with the BrainPrint package (21) based on the FreeSurfer output. For each individual, we calculated the first, i.e., the smallest, 50 eigenvalues of each brain structure as done in (6). Because the first eigenvalue is always zero, since each object is a closed surface without boundary, we used only the next 49 values in our analyses. Each eigenvalue $\lambda_{i,m}$ was further normalized to volume V_i of each brain structure *i*. Volume and surface area were calculated by BrainPrint. Afterwards $\lambda_{i,m}$ was divided by its position *m* in the ordered spectrum to balance out the higher eigenvalues which more likely represent noise (6, 13, 21):

571

572

$$\bar{\lambda}_{i,m} = \frac{1}{m} (\lambda_{i,m} \cdot V_i^{\frac{2}{3}}), \forall i \in \{1, \dots, 22\}, m \in \{2, \dots, 50\}$$

573

In the end, we analyzed 22 brain structures as provided by FreeSurfer: 4th ventricle, brain stem, accumbens area (left and right), amygdala (left and right), caudate (left and right), cerebellum cortex (left and right), cerebellum white matter (left and right), hippocampus (left and right), pallidum (left and right), putamen (left and right), thalamus proper (left and right), ventral diencephalon (DC) (left and right). By that, we handled the normalized and reweighted LBS $\{\bar{\lambda}_{i,2}, ..., \bar{\lambda}_{i,50}\}$ for each brain structure *i* as a 49-dimensional quantitative trait.

580

581 Multivariate Genome-wide Association Analysis

582

For our multivariate GWAS, we used the MOSTest tool, a multivariate omnibus test, which 583 handles big data efficiently and accounts for the correlation among the phenotypes to increase 584 statistical power (2). Since the eigenvalues are not independent in general (Pearson correlation 585 range: [0.285;0.998], mean±SD 0.93±0.06, Fig. S10-S12), we conducted, for each brain structure 586 *i*, a multivariate GWAS on the 49 volume-normalized and scaled eigenvalues $\bar{\lambda}_{i,m}$, m \in 587 {2, ..., 50}, treating each $\bar{\lambda}_{i,m}$ as a single quantitative phenotype. For that, we first calculated 588 residuals of the multidimensional phenotype to control for potential covariates as recommended 589 by MOSTest, i.e., we regressed each $\bar{\lambda}_{im}$ on age, age², sex, first 10 genetic principal components 590 (PCs), Euler number, surface area of each brain structure *i* and the total brain volume. The latter 591 was calculated as the sum of the volume of ventricular cerebrospinal fluid (data field 25004) and 592 the gray and white matter volume (data field 25010) in line with Jansen et al. (1). Normalizing the 593 LBS to volume as described above and regressing out total brain volume and surface area of each 594

- brain structure assured that we indeed studied the shape and not linear size effects. We defined the 595 residualized eigenvalues $\tilde{\lambda}_{i,m}$ as the sum of the estimated intercept and the residuals of its linear 596 regression. After adjusting for covariates, the range of absolute correlations between all $\tilde{\lambda}_{im}$ was 597 quite high (Pearson correlation range: [0;0.978], mean±SD 0.65±0.18, Fig. S10-S12). We further 598 inspected the relation of each $\tilde{\lambda}_{im}$ to volume and surface area by calculating their Pearson 599 correlations. There was, as expected, no correlation with surface area and a low correlation with 600 volume (average r = 0.28) (Fig. S13). The effect was small except for the eigenvalues of caudate, 601 which showed a mean correlation of 0.50 (left) and 0.45 (right), likely relating to the long C-602 shaped form of that structure and by the fact that volume normalization (i.e. multiplication with 603 $V_i^{\bar{3}}$, see above) excludes the pure size effects but not a real difference in shape. Including volume 604 as additional covariate in the MOSTest analysis produced nevertheless similar results (Table 605 S17). 606 All $\tilde{\lambda}_{i,m}$ were then passed to MOSTest, which first performs a rank-based inverse-normal 607 transformation (INT) to obtain normally distributed data. This is followed by a standard additive 608 univariate GWAS for each $\tilde{\lambda}_{i,m}$, resulting in z-scores for each SNP and $\tilde{\lambda}_{i,m}$. This procedure is 609 repeated with once-permuted genotypes, preserving phenotype correlation. The MOSTest test 610
- statistic for a SNP is then calculated as the Mahalanobis norm of the non-permuted z-scores of 611 that SNP and the correlation matrix R of the z-scores from once-permuted genotypes of all 612 eigenvalues. The p-value of the multivariate test statistic is then calculated from a cumulative 613 distribution function of a fitted gamma distribution, which eliminates the need for a multiple 614 testing correction of 49 univariate GWASs and therefore allows to determine significance of 615
- SNPs with a p-value below the standard genome-wide threshold of 5E-8. We further confirmed 616 that MOSTest controlled the type-I error sufficiently by plotting p-values from empirical 617 distributions of the test statistic and from fitted gamma functions under the null hypothesis as 618 calculated by permutating the phenotype-genotype assignments (Fig. S14-S35). 619
- 620

Identification of Genomic Loci and Functional Annotations 621

622

- For functional annotations, we used the web-based platform FUMA (v1.5.6) (29). We used 623 default settings to determine genomic risk loci. First, independent significant SNPs were 624 identified as the ones with p-value equal to or smaller than 2.27E-9 (Bonferroni correction for 22 625 brain structures 5E-8/22 = 2.27E-9) and linkage disequilibrium (LD) with other such SNPs in its 626 vicinity of $r^2 < 0.6$. These SNPs and those in LD with them ($r^2 \ge 0.6$) were defined as 627 candidate SNPs and used in subsequent analyses. LD computation was based on the European 628 population within the 1000 genomes reference panel (phase 3) (95). Those with $r^2 < 0.1$ were 629 classified as lead SNPs among the independent significant SNPs. Independent significant SNPs 630 with $r_2 \ge 0.1$, or with a gap of less than 250 kb between their respective LD blocks (all SNPs in 631
- LD $r2 \ge 0.6$ with them) were merged into one genomic risk locus. Therefore, a genomic risk 632 633 locus can contain multiple independent significant SNPs.
- Candidate SNPs were used for functional annotations. Positional annotation was performed with 634 ANNOVAR (30). Further, SNPs were annotated with CADD scores, RegulomeDB scores, and 635 15-core chromatin states. The major histocompatibility (MHC) region was excluded from all 636 annotations. For eQTL mapping, we checked several available databases containing relevant 637 information, i.e., PsychENCODE eOTLs, ComminMind Consortium, BRAINEAC, and GTEx v8 638
- 639 Brain, and extracted all significant SNP-gene pairs with a False Discovery Rate (FDR, Benjamini-Hochberg procedure(46)) controlled p-value < 0.05 within the respective database. 640
- 641
- 642

643 Gene-mapping and Gene-enrichment Analysis

- 644
- For gene prioritization, we used PoPS (v 0.2) (44), a tool that assigns polygenic priority scores to
- each gene by fitting their MAGMA z-scores by trait-relevant gene features extracted from cell-
- 647 type-specific gene expression, biological pathways and protein-protein interactions. We
- calculated these z-scores using MAGMA (v 1.10) (41) by first annotating SNPs to 18,383 protein-
- 649 coding genes within a 0kb window and afterwards performing gene analysis using the SNP-wise
- 650 mean model and the European population of 1000 Genomes as reference dataset for every brain
- 651 structure. We then ran PoPS on our MAGMA scores using default settings and all available
- 52 57,543 gene features. Gene annotation and location files, as well as gene features, were taken
- 653 from <u>https://www.finucanelab.org/data</u>.
- Lead SNPs, as defined by FUMA (see above), were mapped to genes within a 500kb window up-
- and downstream. We first selected the four genes with the highest PoP score in each locus.
- 656 Second, since it was shown that PoPS works best when combined with orthogonal methods like
 657 Nearest Gene, we mapped each lead SNP to the two closest genes. After assigning a rank to each
 658 gene by both methods and averaging the two ranks, we reranked the genes and finally prioritized
- all genes with average rank ≤ 2 for each independent significant SNP.
- 660 The prioritized genes were given as input to FUMAs Gene2Func tool. Genes of brain structures
- 661 present in both hemispheres were joined in each analysis. We used all protein-coding genes of
- 662 Ensembl v110. Hypergeometric tests analyzed the overrepresentation of mapped genes in
- precalculated gene sets followed by an FDR control (Benjamini-Hochberg, p < 0.05) within each category.

666 Canonical Correlation Analysis with PRS

667

665

For the canonical correlation analysis (CCA), we extracted PRS of 6 brain shape-related traits and 668 disorders and of one trait that stood out from the FUMA gene-set results. 6 PRS were taken from 669 the UK Biobank which have exclusively been trained on external data sets: Alzheimer's disease 670 (data field 26206), bipolar disorder (data field 26214), ischemic stroke (data field 26248), 671 multiple sclerosis (data field 26254), Parkinson's disease (data field 26260) and schizophrenia 672 (data field 26275). Further, we calculated the PRS for alcohol use disorder based on the score 673 definition from the PGScatalog (96) (PGS002738 (97)). UK Biobank data was not used for 674 training in this last score but for one GWAS in the discovery meta-analysis of the alcohol use 675 disorder study. The data was available for 19850 samples. Each PRS was first linearly regressed 676 on age, age², sex, first 10 genetic principal components (PCs), and total brain volume. The 677 residuals were added to the fitted intercept. Second, a rank-based INT was applied to those 678 PRS. The partial correlation between the PRS was calculated as a Pearson correlation. We used 679 the residualized eigenvalues $\tilde{\lambda}_{im}$ as they were used as input for MOSTest for each brain structure 680 and applied a rank-based INT. 681 For each pair of PRS and brain structure, we conducted a CCA using the cca() function within the 682

- ⁶⁸² For each pair of PKS and brain structure, we conducted a CCA using the cca() function within the
 "yacca" R-package (version 1.4-2) (*98*). CCA finds a linear combination of all eigenvalues, a so⁶⁸⁴ called canonical variable, which correlates maximally with the PRS. All resulting p-values of the
 ⁶⁸⁵ correlations were adjusted for multiple testing using FDR. Afterwards, we applied an additional
 ⁶⁸⁶ Bonferroni correction for 6 effective PRS, which we consider as the two-level correction. For
 ⁶⁸⁷ comparison, we also calculated the Bonferroni correction for 22*6 tests. All adjustments were
 ⁶⁸⁸ made to the 0.05 significance threshold.
- 689 Further, in each CCA, we investigated the loadings, i.e. the correlations of all eigenvalues with
- 690 their canonical variable, which describe the direction and strength of the impact of each
- 691 eigenvalue on the risk score. Out of those, we calculated the mean loading and the number of
- negative/positive loadings of all eigenvalues in each brain structure and PRS. If at least 90% of all

loadings had the same direction, we deemed that as a common direction of effects. Hierarchical
 clusters were computed on the distances of mean loadings among brain structures and PRS,
 respectively, using the complete linkage method (Fig. S7).

697 SNP-based Heritability

698

696

699 Ge et al. investigated the heritability of neuroanatomical shape using the LBS. For estimating its 700 SNP-heritability, they proposed a multidimensional approach where they summed the univariate 701 heritability h_m^2 of the eigenvalues, each weighted by γ_m , the relative size of its phenotypic 702 variance:

703 704

$$h^2 = \sum_m \gamma_m h_m^2$$
, with $\gamma_m = \frac{\sigma_{P_m}^2}{\sum_k \sigma_{P_k}^2}$

705

and $\sigma_{P_m}^2$ being the phenotypic variance of trait *m*. The univariate heritabilities of the 49 eigenvalues were derived using SCORE. For combined structures, we derived the multidimensional heritability from the union set of eigenvalues. When applying SCORE, we proceeded as with the GWAS described above, using volume-normalized and reweighted eigenvalues and the same set of covariates. The phenotypic variance was also computed using the residualized eigenvalues $\tilde{\lambda}_{i,m}$. We further calculated the p-value of each heritability using the Wald test statistics, which is distributed as

$$\left(\frac{h^2}{SE(h^2)}\right)^2 \sim \frac{1}{2}\chi_0^2 + \frac{1}{2}\chi_1^2$$

715

714

With χ_0^2 being the point mass at 0 and χ_1^2 the chi-squared distribution with one degree of freedom since the null hypothesis H_0 : $h^2 = 0$ lies on the boundary of a constrained parameter space ($h^2 \ge$ 0) (99). The standard error (SE) of each multidimensional heritability was calculated using Bienayme's identity for the variance of a sum and the univariate estimates from SCORE as follows:

$$SE(h^2) = \sqrt{\sum_m \gamma_m^2 SE(h_m^2)^2}$$

723

726

727

722

For testing the difference between heritability values in each combined brain structure, weutilized the Wald test statistics distributed as

$$\left(\frac{h^2-h_{Ge}^2}{SE(h^2-h_{Ge}^2)}\right)^2\sim\chi_1^2,$$

728 729 with

- 730 731
- 732

 $SE(h^2 - h_{Ge}^2)^2 = SE(h^2)^2 + SE(h_{Ge}^2)^2 - SE(h^2)SE(h_{Ge}^2)cor(h^2, h_{Ge}^2).$

Since $SE(h^2)$ is small in comparison to $SE(h_{Ge}^2)$, we can approximate $SE(h^2 - h_{Ge}^2)^2$ by just $SE(h_{Ge}^2)^2$.

735 736

737 **Replication**

738

Replication analysis was conducted on the 20% sample (see above). This encompassed 4963

ranging in age rangin

from 45.2 to 81.8 years (age mean \pm SD: 64.2 \pm 7.4, female: 63.6 \pm 7.2, male: 64.9 \pm 7.6). We used

the same procedure and set of covariates to perform MOSTest analyses for each brain structure on

this dataset and all SNPs passing QC. For each brain structure, we only investigated those variants

of the 80 independent SNPs which had shown Bonferroni corrected genome-wide significance in

the respective discovery GWAS. FDR correction was applied to these p-values for each brain

- 746 structure separately.
- 747

748

749

750 **References**

751 752 P. R. Jansen, M. Nagel, K. Watanabe, Y. Wei, J. E. Savage, C. A. De Leeuw, M. P. Van Den Heuvel, S. Van 1. 753 Der Sluis, D. Posthuma, Genome-wide meta-analysis of brain volume identifies genomic loci and genes shared with 754 intelligence. Nat Commun 11, 5606 (2020). 755 D. Van Der Meer, O. Frei, T. Kaufmann, A. A. Shadrin, A. Devor, O. B. Smeland, W. K. Thompson, C. C. 2. 756 Fan, D. Holland, L. T. Westlye, O. A. Andreassen, A. M. Dale, Understanding the genetic determinants of the brain 757 with MOSTest. Nat Commun 11, 3512 (2020). 758 D. P. Hibar, J. L. Stein, M. E. Renteria, A. Arias-Vasquez, S. Desrivières, N. Jahanshad, R. Toro, K. 3. 759 Wittfeld, L. Abramovic, M. Andersson, B. S. Aribisala, N. J. Armstrong, M. Bernard, M. M. Bohlken, M. P. Boks, J. 760 Bralten, A. A. Brown, M. Mallar Chakravarty, Q. Chen, C. R. K. Ching, G. Cuellar-Partida, A. den Braber, S. 761 Giddaluru, A. L. Goldman, O. Grimm, T. Guadalupe, J. Hass, G. Woldehawariat, A. J. Holmes, M. Hoogman, D. 762 Janowitz, T. Jia, S. Kim, M. Klein, B. Kraemer, P. H. Lee, L. M. Olde Loohuis, M. Luciano, C. Macare, K. A. 763 Mather, M. Mattheisen, Y. Milaneschi, K. Nho, M. Papmeyer, A. Ramasamy, S. L. Risacher, R. Roiz-Santiañez, E. J. 764 Rose, A. Salami, P. G. Sämann, L. Schmaal, A. J. Schork, J. Shin, L. T. Strike, A. Teumer, M. M. J. van Donkelaar, 765 K. R. van Eijk, R. K. Walters, L. T. Westlye, C. D. Whelan, A. M. Winkler, M. P. Zwiers, S. Alhusaini, L. Athanasiu, S. Ehrlich, M. M. H. Hakobjan, C. B. Hartberg, U. K. Haukvik, A. J. G. A. M. Heister, D. Hoehn, D. Kasperaviciute, 766 D. C. M. Liewald, L. M. Lopez, R. R. R. Makkinje, M. Matarin, M. A. M. Naber, D. Reese McKay, M. Needham, A. 767 768 C. Nugent, B. Pütz, N. A. Royle, L. Shen, E. Sprooten, D. Trabzuni, S. S. L. van der Marel, K. J. E. van Hulzen, E. 769 Walton, C. Wolf, L. Almasy, D. Ames, S. Arepalli, A. A. Assareh, M. E. Bastin, H. Brodaty, K. B. Bulaveva, M. A. 770 Carless, S. Cichon, A. Corvin, J. E. Curran, M. Czisch, G. I. de Zubicaray, A. Dillman, R. Duggirala, T. D. Dver, S. 771 Erk, I. O. Fedko, L. Ferrucci, T. M. Foroud, P. T. Fox, M. Fukunaga, J. Raphael Gibbs, H. H. H. Göring, R. C. Green, 772 S. Guelfi, N. K. Hansell, C. A. Hartman, K. Hegenscheid, A. Heinz, D. G. Hernandez, D. J. Heslenfeld, P. J. 773 Hoekstra, F. Holsboer, G. Homuth, J.-J. Hottenga, M. Ikeda, C. R. Jack, M. Jenkinson, R. Johnson, R. Kanai, M. 774 Keil, J. W. Kent, P. Kochunov, J. B. Kwok, S. M. Lawrie, X. Liu, D. L. Longo, K. L. McMahon, E. Meisenzahl, I. 775 Melle, S. Mohnke, G. W. Montgomery, J. C. Mostert, T. W. Mühleisen, M. A. Nalls, T. E. Nichols, L. G. Nilsson, M. 776 M. Nöthen, K. Ohi, R. L. Olvera, R. Perez-Iglesias, G. Bruce Pike, S. G. Potkin, I. Reinvang, S. Reppermund, M. 777 Rietschel, N. Romanczuk-Seiferth, G. D. Rosen, D. Rujescu, K. Schnell, P. R. Schofield, C. Smith, V. M. Steen, J. E. 778 Sussmann, A. Thalamuthu, A. W. Toga, B. J. Traynor, J. Troncoso, J. A. Turner, M. C. Valdés Hernández, D. van 't 779 Ent, M. van der Brug, N. J. A. van der Wee, M.-J. van Tol, D. J. Veltman, T. H. Wassink, E. Westman, R. H. Zielke, 780 A. B. Zonderman, D. G. Ashbrook, R. Hager, L. Lu, F. J. McMahon, D. W. Morris, R. W. Williams, H. G. Brunner, 781 R. L. Buckner, J. K. Buitelaar, W. Cahn, V. D. Calhoun, G. L. Cavalleri, B. Crespo-Facorro, A. M. Dale, G. E. 782 Davies, N. Delanty, C. Depondt, S. Djurovic, W. C. Drevets, T. Espeseth, R. L. Gollub, B.-C. Ho, W. Hoffmann, N. 783 Hosten, R. S. Kahn, S. Le Hellard, A. Meyer-Lindenberg, B. Müller-Myhsok, M. Nauck, L. Nyberg, M. Pandolfo, B. 784 W. J. H. Penninx, J. L. Roffman, S. M. Sisodiya, J. W. Smoller, H. van Bokhoven, N. E. M. van Haren, H. Völzke, 785 H. Walter, M. W. Weiner, W. Wen, T. White, I. Agartz, O. A. Andreassen, J. Blangero, D. I. Boomsma, R. M. Brouwer, D. M. Cannon, M. R. Cookson, E. J. C. de Geus, I. J. Deary, G. Donohoe, G. Fernández, S. E. Fisher, C. 786 787 Francks, D. C. Glahn, H. J. Grabe, O. Gruber, J. Hardy, R. Hashimoto, H. E. Hulshoff Pol, E. G. Jönsson, I. 788 Kloszewska, S. Lovestone, V. S. Mattay, P. Mecocci, C. McDonald, A. M. McIntosh, R. A. Ophoff, T. Paus, Z. Pausova, M. Ryten, P. S. Sachdev, A. J. Saykin, A. Simmons, A. Singleton, H. Soininen, J. M. Wardlaw, M. E. 789 790 Weale, D. R. Weinberger, H. H. H. Adams, L. J. Launer, S. Seiler, R. Schmidt, G. Chauhan, C. L. Satizabal, J. T. 791 Becker, L. Yanek, S. J. van der Lee, M. Ebling, B. Fischl, W. T. Longstreth, D. Greve, H. Schmidt, P. Nyquist, L. N. 792 Vinke, C. M. van Duijn, L. Xue, B. Mazoyer, J. C. Bis, V. Gudnason, S. Seshadri, M. A. Ikram, N. G. Martin, M. J. 793 Wright, G. Schumann, B. Franke, P. M. Thompson, S. E. Medland, Common genetic variants influence human 794 subcortical brain structures. Nature 520, 224-229 (2015). 795 C. L. Satizabal, H. H. H. Adams, D. P. Hibar, C. C. White, M. J. Knol, J. L. Stein, M. Scholz, M. 4. 796 Sargurupremraj, N. Jahanshad, G. V. Roshchupkin, A. V. Smith, J. C. Bis, X. Jian, M. Luciano, E. Hofer, A. Teumer, 797 S. J. Van Der Lee, J. Yang, L. R. Yanek, T. V. Lee, S. Li, Y. Hu, J. Y. Koh, J. D. Eicher, S. Desrivières, A. Arias-798 Vasquez, G. Chauhan, L. Athanasiu, M. E. Rentería, S. Kim, D. Hoehn, N. J. Armstrong, O. Chen, A. J. Holmes, A. 799 Den Braber, I. Kloszewska, M. Andersson, T. Espeseth, O. Grimm, L. Abramovic, S. Alhusaini, Y. Milaneschi, M. 800 Papmever, T. Axelsson, S. Ehrlich, R. Roiz-Santiañez, B. Kraemer, A. K. Håberg, H. J. Jones, G. B. Pike, D. J. Stein, 801 A. Stevens, J. Bralten, M. W. Vernooij, T. B. Harris, I. Filippi, A. V. Witte, T. Guadalupe, K. Wittfeld, T. H. Mosley, 802 J. T. Becker, N. T. Doan, S. P. Hagenaars, Y. Saba, G. Cuellar-Partida, N. Amin, S. Hilal, K. Nho, N. Mirza-803 Schreiber, K. Arfanakis, D. M. Becker, D. Ames, A. L. Goldman, P. H. Lee, D. I. Boomsma, S. Lovestone, S. 804 Giddaluru, S. Le Hellard, M. Mattheisen, M. M. Bohlken, D. Kasperaviciute, L. Schmaal, S. M. Lawrie, I. Agartz, E. 805 Walton, D. Tordesillas-Gutierrez, G. E. Davies, J. Shin, J. C. Ipser, L. N. Vinke, M. Hoogman, T. Jia, R. Burkhardt, 806 M. Klein, F. Crivello, D. Janowitz, O. Carmichael, U. K. Haukvik, B. S. Aribisala, H. Schmidt, L. T. Strike, C.-Y. 807 Cheng, S. L. Risacher, B. Pütz, D. A. Fleischman, A. A. Assareh, V. S. Mattay, R. L. Buckner, P. Mecocci, A. M. 808 Dale, S. Cichon, M. P. Boks, M. Matarin, B. W. J. H. Penninx, V. D. Calhoun, M. M. Chakravarty, A. F. Marquand, 809 C. Macare, S. Kharabian Masouleh, J. Oosterlaan, P. Amouvel, K. Hegenscheid, J. I. Rotter, A. J. Schork, D. C. M.

810 Liewald, G. I. De Zubicaray, T. Y. Wong, L. Shen, P. G. Sämann, H. Brodaty, J. L. Roffman, E. J. C. De Geus, M. 811 Tsolaki, S. Erk, K. R. Van Eijk, G. L. Cavalleri, N. J. A. Van Der Wee, A. M. McIntosh, R. L. Gollub, K. B. 812 Bulayeva, M. Bernard, J. S. Richards, J. J. Himali, M. Loeffler, N. Rommelse, W. Hoffmann, L. T. Westlve, M. C. Valdés Hernández, N. K. Hansell, T. G. M. Van Erp, C. Wolf, J. B. J. Kwok, B. Vellas, A. Heinz, L. M. Olde 813 Loohuis, N. Delanty, B.-C. Ho, C. R. K. Ching, E. Shumskaya, B. Singh, A. Hofman, D. Van Der Meer, G. Homuth, 814 815 B. M. Psaty, M. E. Bastin, G. W. Montgomery, T. M. Foroud, S. Reppermund, J.-J. Hottenga, A. Simmons, A. 816 Meyer-Lindenberg, W. Cahn, C. D. Whelan, M. M. J. Van Donkelaar, Q. Yang, N. Hosten, R. C. Green, A. Thalamuthu, S. Mohnke, H. E. Hulshoff Pol, H. Lin, C. R. Jack, P. R. Schofield, T. W. Mühleisen, P. Maillard, S. G. 817 Potkin, W. Wen, E. Fletcher, A. W. Toga, O. Gruber, M. Huentelman, G. Davey Smith, L. J. Launer, L. Nyberg, E. 818 819 G. Jönsson, B. Crespo-Facorro, N. Koen, D. N. Greve, A. G. Uitterlinden, D. R. Weinberger, V. M. Steen, I. O. 820 Fedko, N. A. Groenewold, W. J. Niessen, R. Toro, C. Tzourio, W. T. Longstreth, M. K. Ikram, J. W. Smoller, M.-J. 821 Van Tol, J. E. Sussmann, T. Paus, H. Lemaître, M. L. Schroeter, B. Mazover, O. A. Andreassen, F. Holsboer, C. 822 Depondt, D. J. Veltman, J. A. Turner, Z. Pausova, G. Schumann, D. Van Rooij, S. Djurovic, I. J. Deary, K. L. 823 McMahon, B. Müller-Myhsok, R. M. Brouwer, H. Soininen, M. Pandolfo, T. H. Wassink, J. W. Cheung, T. Wolfers, 824 J.-L. Martinot, M. P. Zwiers, M. Nauck, I. Melle, N. G. Martin, R. Kanai, E. Westman, R. S. Kahn, S. M. Sisodiya, T. 825 White, A. Saremi, H. Van Bokhoven, H. G. Brunner, H. Völzke, M. J. Wright, D. Van 'T Ent, M. M. Nöthen, R. A. 826 Ophoff, J. K. Buitelaar, G. Fernández, P. S. Sachdev, M. Rietschel, N. E. M. Van Haren, S. E. Fisher, A. S. Beiser, C. 827 Francks, A. J. Saykin, K. A. Mather, N. Romanczuk-Seiferth, C. A. Hartman, A. L. DeStefano, D. J. Heslenfeld, M. 828 W. Weiner, H. Walter, P. J. Hoekstra, P. A. Nyquist, B. Franke, D. A. Bennett, H. J. Grabe, A. D. Johnson, C. Chen, 829 C. M. Van Duijn, O. L. Lopez, M. Fornage, J. M. Wardlaw, R. Schmidt, C. DeCarli, P. L. De Jager, A. Villringer, S. 830 Debette, V. Gudnason, S. E. Medland, J. M. Shulman, P. M. Thompson, S. Seshadri, M. A. Ikram, Genetic architecture of subcortical brain structures in 38,851 individuals. Nat Genet 51, 1624–1636 (2019). 831 832 5. T. Elvsåshagen, S. Bahrami, D. Van Der Meer, I. Agartz, D. Alnæs, D. M. Barch, R. Baur-Streubel, A. 833 Bertolino, M. K. Bever, G. Blasi, S. Borgwardt, B. Bove, J. Buitelaar, E. Bøen, E. G. Celius, S. Cervenka, A. 834 Conzelmann, D. Coynel, P. Di Carlo, S. Djurovic, S. Eisenacher, T. Espeseth, H. Fatouros-Bergman, L. Flyckt, B. 835 Franke, O. Frei, B. Gelao, H. F. Harbo, C. A. Hartman, A. Håberg, D. Heslenfeld, P. J. Hoekstra, E. A. Høgestøl, R. 836 Jonassen, E. G. Jönsson, Karolinska Schizophrenia Project (KaSP) consortium, L. Farde, L. Flyckt, G. Engberg, S. Erhardt S, H. Fatouros-Bergman, S. Cervenka, L. Schwieler, F. Piehl, I. Agartz, K. Collste, P. Victorsson, A. 837 838 Malmqvist, M. Hedberg, F. Orhan, C. M. Sellgren, P. Kirsch, I. Kłoszewska, T. V. Lagerberg, N. I. Landrø, S. Le 839 Hellard, K.-P. Lesch, L. A. Maglanoc, U. F. Malt, P. Mecocci, I. Melle, A. Meyer-Lindenberg, T. Moberget, J. E. 840 Nordvik, L. Nyberg, K. S. O. Connell, J. Oosterlaan, M. Papalino, A. Papassotiropoulos, P. Pauli, G. Pergola, K. 841 Persson, D. De Quervain, A. Reif, J. Rokicki, D. Van Rooij, A. A. Shadrin, A. Schmidt, E. Schwarz, G. Selbæk, H. 842 Soininen, P. Sowa, V. M. Steen, M. Tsolaki, B. Vellas, L. Wang, E. Westman, G. C. Ziegler, M. Zink, O. A. 843 Andreassen, L. T. Westlye, T. Kaufmann, The genetic architecture of human brainstem structures and their 844 involvement in common brain disorders. Nat Commun 11, 4016 (2020). 845 T. Ge, M. Reuter, A. M. Winkler, A. J. Holmes, P. H. Lee, L. S. Tirrell, J. L. Roffman, R. L. Buckner, J. W. 6. 846 Smoller, M. R. Sabuncu, Multidimensional heritability analysis of neuroanatomical shape. Nat Commun 7, 13291 847 (2016). 848 G. V. Roshchupkin, B. A. Gutman, M. W. Vernooij, N. Jahanshad, N. G. Martin, A. Hofman, K. L. 7. 849 McMahon, S. J. Van Der Lee, C. M. Van Duijn, G. I. De Zubicaray, A. G. Uitterlinden, M. J. Wright, W. J. Niessen, 850 P. M. Thompson, M. A. Ikram, H. H. H. Adams, Heritability of the shape of subcortical brain structures in the 851 general population. Nat Commun 7, 13738 (2016). B. A. Gutman, T. G. M. Van Erp, K. Alpert, C. R. K. Ching, D. Isaev, A. Ragothaman, N. Jahanshad, A. 852 8. 853 Saremi, A. Zavaliangos-Petropulu, D. C. Glahn, L. Shen, S. Cong, D. Alnæs, O. A. Andreassen, N. T. Doan, L. T. Westlye, P. Kochunov, T. D. Satterthwaite, D. H. Wolf, A. J. Huang, C. Kessler, A. Weideman, D. Nguyen, B. A. 854 855 Mueller, L. Faziola, S. G. Potkin, A. Preda, D. H. Mathalon, J. Bustillo, V. Calhoun, J. M. Ford, E. Walton, S. 856 Ehrlich, G. Ducci, N. Banaj, F. Piras, F. Piras, G. Spalletta, E. J. Canales-Rodríguez, P. Fuentes-Claramonte, E. 857 Pomarol-Clotet, J. Radua, R. Salvador, S. Sarró, E. W. Dickie, A. Voineskos, D. Tordesillas-Gutiérrez, B. Crespo-858 Facorro, E. Setién-Suero, J. M. Van Son, S. Borgwardt, F. Schönborn-Harrisberger, D. Morris, G. Donohoe, L. 859 Holleran, D. Cannon, C. McDonald, A. Corvin, M. Gill, G. B. Filho, P. G. P. Rosa, M. H. Serpa, M. V. Zanetti, I. Lebedeva, V. Kaleda, A. Tomyshev, T. Crow, A. James, S. Cervenka, C. M. Sellgren, H. Fatouros-Bergman, I. 860 861 Agartz, F. Howells, D. J. Stein, H. Temmingh, A. Uhlmann, G. I. De Zubicaray, K. L. McMahon, M. Wright, D. Cobia, J. G. Csernansky, P. M. Thompson, J. A. Turner, L. Wang, A META-ANALYSIS of deep brain structural shape 862 and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the 863 864 ENIGMA CONSORTIUM. Human Brain Mapping 43, 352–372 (2022). L. T. Elliott, K. Sharp, F. Alfaro-Almagro, S. Shi, K. L. Miller, G. Douaud, J. Marchini, S. M. Smith, 865 9. 866 Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature 562, 210–216 (2018). C. C. Fan, R. Loughnan, C. Makowski, D. Pecheva, C.-H. Chen, D. J. Hagler, W. K. Thompson, N. Parker, 867 10. 868 D. van der Meer, O. Frei, O. A. Andreassen, A. M. Dale, Multivariate genome-wide association study on tissue-869 sensitive diffusion metrics highlights pathways that shape the human brain. Nat Commun 13, 2423 (2022). 870 11. S. Goovaerts, H. Hoskens, R. J. Eller, N. Herrick, A. M. Musolf, C. M. Justice, M. Yuan, S. Naqvi, M. K.

871	Lee, D. Vandermeulen, H. L. Szabo-Rogers, P. A. Romitti, S. A. Boyadjiev, M. L. Marazita, J. R. Shaffer, M. D.
872	Shriver, J. Wysocka, S. Walsh, S. M. Weinberg, P. Claes, Joint multi-ancestry and admixed GWAS reveals the
873	complex genetics behind human cranial vault shape. Nat Commun 14, 7436 (2023).
874	12. S. Nagvi, Y. Slevp, H. Hoskens, K. Indencleef, J. P. Spence, R. Bruffaerts, A. Radwan, R. J. Eller, S.
875	Richmond, M. D. Shriver, J. R. Shaffer, S. M. Weinberg, S. Walsh, J. Thompson, J. K. Pritchard, S. Sunaert, H.
876	Peeters, J. Wysocka, P. Claes, Shared heritability of human face and brain shape. <i>Nat Genet</i> 53 , 830–839 (2021).
877	13. M. Reuter, FE. Wolter, N. Peinecke, Laplace–Beltrami spectra as 'Shape-DNA' of surfaces and solids.
878	Computer-Aided Design 38 342–366 (2006)
879	14 M Reuter, FF. Wolter, N. Peinecke, "Lanlace-spectra as fingerprints for shape matching" in <i>Proceedings</i>
880	of the 2005 ACM Symposium on Solid and Physical Modeling (ACM Cambridge Massachusetts 2005:
881	https://dl.acm.org/doi/10.1145/1060244.1060256).pp. 101–106
887	15 E E E Chladni Entdackungan über die Theorie des Klanges (bev Weidmanns Erben und Reich 1787)
883	https://www.e.rara.ch/zut/doi/10.3031/e.rara.4235)
884	$16 \qquad M Kac Can One Hear the Share of a Drum? The American Mathematical Monthly 73 1 (1966)$
885	17. C. Gordon D. L. Webb S. Wolnert. One connot bear the share of a drum. Bull. Amar. Math. Soc. 27, 134
885	17. C. Oordon, D. L. webb, S. wolpert, One cannot near the shape of a drum. <i>Butt. Amer. Muth. Soc.</i> $27, 154-128$ (1002)
000	130 (1772). 18 S. Zalditah Inverse greated neablem for analytic domains $H_1 \mathbb{Z}_2$, symmetric domains $Ann Math 170$
007	205, 260 (2000)
000	203-209 (2009).
009	19. M. Reuler, FE. Woller, M. Shenion, M. Nieulannier, Laplace–Beltraini eigenvalues and topological
890 801	Teatures of eigenfunctions for statistical shape analysis. Computer-Alded Design 41, 759–755 (2009).
891	20. H. P. McKean, Jr., I. M. Singer, Curvature and the eigenvalues of the Laplacian. J. Dijjerential Geom. 1
892	(1907). 21 C. Weshingen D. Celland W. Kremen, D. Fiechl M. Dauter, Durin Drint, A. discrimination share staring star
893	21. C. wachinger, P. Golland, W. Kremen, B. Fischi, M. Reuter, BrainPrint: A discriminative characterization
894	of brain morphology. <i>NeuroImage</i> 109, 232–248 (2015).
895	22. M. Niethammer, M. Reuter, FE. Wolter, S. Bouix, N. Peinecke, MS. Koo, M. E. Shenton, "Global
896	Medical Shape Analysis Using the Laplace-Beltrami Spectrum" in Medical Image Computing and Computer-Assisted
897	Intervention – MICCAI 200/, N. Ayache, S. Ourselin, A. Maeder, Eds. (Springer Berlin Heidelberg, Berlin,
898	Heidelberg, 2007; http://link.springer.com/10.1007/978-3-540-75757-3_103)vol. 4791 of <i>Lecture Notes in Computer</i>
899	Science, pp. 850–857.
900	23. J. C. Pang, K. M. Aquino, M. Oldehinkel, P. A. Robinson, B. D. Fulcher, M. Breakspear, A. Fornito,
901	Geometric constraints on human brain function. <i>Nature</i> 618 , 566–574 (2023).
902	24. D. Van Der Meer, A. A. Shadrin, K. O'Connell, F. Bettella, S. Djurovic, T. Wolfers, D. Alnæs, I. Agartz, O.
903	B. Smeland, I. Melle, J. M. Sánchez, D. E. J. Linden, A. M. Dale, L. T. Westlye, O. A. Andreassen, O. Frei, T.
904	Kaufmann, Boosting Schizophrenia Genetics by Utilizing Genetic Overlap With Brain Morphology. <i>Biological</i>
905	<i>Psychiatry</i> 92 , 291–298 (2022).
906	25. S. Bahrami, K. Nordengen, A. A. Shadrin, O. Frei, D. Van Der Meer, A. M. Dale, L. T. Westlye, O. A.
907	Andreassen, T. Kaufmann, Distributed genetic architecture across the hippocampal formation implies common
908	neuropathology across brain disorders. <i>Nat Commun</i> 13 , 3436 (2022).
909	26. T. Elvsåshagen, A. Shadrin, O. Frei, D. Van Der Meer, S. Bahrami, V. J. Kumar, O. Smeland, L. T. Westlye,
910	O. A. Andreassen, T. Kaufmann, The genetic architecture of the human thalamus and its overlap with ten common
911	brain disorders. Nat Commun 12, 2909 (2021).
912	27. H. H. Yin, B. J. Knowlton, The role of the basal ganglia in habit formation. <i>Nat Rev Neurosci</i> 7, 464–476
913	(2006).
914	28. L. T. Grinberg, U. Rueb, H. Heinsen, Brainstem: Neglected Locus in Neurodegenerative Diseases. <i>Front.</i>
915	<i>Neur.</i> 2 (2011).
916	29. K. Watanabe, E. Taskesen, A. van Bochoven, D. Posthuma, Functional mapping and annotation of genetic
917	associations with FUMA. Nat Commun 8, 1826 (2017).
918	30. K. Wang, M. Li, H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high-
919	throughput sequencing data. Nucleic Acids Research 38, e164 (2010).
920	31. M. Kircher, D. M. Witten, P. Jain, B. J. O'Roak, G. M. Cooper, J. Shendure, A general framework for
921	estimating the relative pathogenicity of human genetic variants. Nat Genet 46, 310-315 (2014).
922	32. M. J. Landrum, S. Chitipiralla, G. R. Brown, C. Chen, B. Gu, J. Hart, D. Hoffman, W. Jang, K. Kaur, C. Liu,
923	V. Lyoshin, Z. Maddipatla, R. Maiti, J. Mitchell, N. O'Leary, G. R. Riley, W. Shi, G. Zhou, V. Schneider, D.
924	Maglott, J. B. Holmes, B. L. Kattman, ClinVar: improvements to accessing data. Nucleic Acids Res 48, D835–D844
925	(2020).
926	33. J. Cheng, G. Novati, J. Pan, C. Bycroft, A. Žemgulytė, T. Applebaum, A. Pritzel, L. H. Wong, M. Zielinski,
927	T. Sargeant, R. G. Schneider, A. W. Senior, J. Jumper, D. Hassabis, P. Kohli, Ž. Avsec, Accurate proteome-wide
928	missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).
929	34. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Biological insights from 108
930	schizophrenia-associated genetic loci. Nature 511, 421-427 (2014).
931	35. N. Carrera, M. Arrojo, J. Sanjuán, R. Ramos-Ríos, E. Paz, J. J. Suárez-Rama, M. Páramo, S. Agra, J.

- 932 Brenlla, S. Martínez, O. Rivero, D. A. Collier, A. Palotie, S. Cichon, M. M. Nöthen, M. Rietschel, D. Rujescu, H.
- 933 Stefansson, S. Steinberg, E. Sigurdsson, D. St. Clair, S. Tosato, T. Werge, K. Stefansson, J. C. González, J. Valero,
- 934 A. Gutiérrez-Zotes, A. Labad, L. Martorell, E. Vilella, Á. Carracedo, J. Costas, Association Study of
- Nonsynonymous Single Nucleotide Polymorphisms in Schizophrenia. *Biological Psychiatry* 71, 169–177 (2012).
- 936 36. GERAD1 Consortium, CRESTAR Consortium, A. F. Pardiñas, P. Holmans, A. J. Pocklington, V. Escott-
- 937 Price, S. Ripke, N. Carrera, S. E. Legge, S. Bishop, D. Cameron, M. L. Hamshere, J. Han, L. Hubbard, A. Lynham,
- 938 K. Mantripragada, E. Rees, J. H. MacCabe, S. A. McCarroll, B. T. Baune, G. Breen, E. M. Byrne, U. Dannlowski, T.
- 939 C. Eley, C. Hayward, N. G. Martin, A. M. McIntosh, R. Plomin, D. J. Porteous, N. R. Wray, A. Caballero, D. H.
- 940 Geschwind, L. M. Huckins, D. M. Ruderfer, E. Santiago, P. Sklar, E. A. Stahl, H. Won, E. Agerbo, T. D. Als, O. A.
- Andreassen, M. Bækvad-Hansen, P. B. Mortensen, C. B. Pedersen, A. D. Børglum, J. Bybjerg-Grauholm, S.
- 942 Djurovic, N. Durmishi, M. G. Pedersen, V. Golimbet, J. Grove, D. M. Hougaard, M. Mattheisen, E. Molden, O.
- Mors, M. Nordentoft, M. Pejovic-Milovancevic, E. Sigurdsson, T. Silagadze, C. S. Hansen, K. Stefansson, H.
 Stefansson, S. Steinberg, S. Tosato, T. Werge, D. A. Collier, D. Rujescu, G. Kirov, M. J. Owen, M. C. O'Donovan, J.
- Stefansson, S. Steinberg, S. Tosato, T. Werge, D. A. Conter, D. Rujescu, G. Knov, M. J. Owen, M. C. O Donovan, J.
 T. R. Walters, Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong
 background selection. *Nat Genet* 50, 381–389 (2018).
- 947 37. D. Li, J.-P. Achkar, T. Haritunians, J. P. Jacobs, K. Y. Hui, M. D'Amato, S. Brand, G. Radford-Smith, J.
- 948 Halfvarson, J.-H. Niess, S. Kugathasan, C. Büning, L. P. Schumm, L. Klei, A. Ananthakrishnan, G. Aumais, L.
- Baidoo, M. Dubinsky, C. Fiocchi, J. Glas, R. Milgrom, D. D. Proctor, M. Regueiro, L. A. Simms, J. M. Stempak, S.
- 950 R. Targan, L. Törkvist, Y. Sharma, B. Devlin, J. Borneman, H. Hakonarson, R. J. Xavier, M. Daly, S. R. Brant, J. D.
- 951 Rioux, M. S. Silverberg, J. H. Cho, J. Braun, D. P. McGovern, R. H. Duerr, A pleiotropic missense variant in
- 952 SLC39A8 is associated with Crohn's disease and human gut microbiome composition. *Gastroenterology* 151, 724–
 953 732 (2016).
- 38. The International Consortium for Blood Pressure Genome-Wide Association Studies., Genetic Variants in
 Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk. *Nature* 478, 103–109 (2011).
- 956 39. T. M. Caffrey, R. Wade-Martins, Functional MAPT haplotypes: Bridging the gap between genotype and 957 neuropathology. *Neurobiology of Disease* **27**, 1–10 (2007).
- 40. M. Wainberg, N. J. Forde, S. Mansour, I. Kerrebijn, S. E. Medland, C. Hawco, S. J. Tripathy, Genetic
 architecture of the structural connectome. *Nat Commun* 15, 1962 (2024).
- 41. C. A. de Leeuw, J. M. Mooij, T. Heskes, D. Posthuma, MAGMA: Generalized Gene-Set Analysis of GWAS
 Data. *PLOS Computational Biology* 11, e1004219 (2015).
- 42. T. Rittman, M. Rubinov, P. E. Vértes, A. X. Patel, C. E. Ginestet, B. C. P. Ghosh, R. A. Barker, M. G.
 Spillantini, E. T. Bullmore, J. B. Rowe, Regional expression of the MAPT gene is associated with loss of hubs in
 brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. *Neurobiology of*
- 965 Aging 48, 153–160 (2016).
- 43. R. S. Desikan, A. J. Schork, Y. Wang, A. Witoelar, M. Sharma, L. K. McEvoy, D. Holland, J. B. Brewer,
- 967 C.-H. Chen, W. K. Thompson, D. Harold, J. Williams, M. J. Owen, M. C. O'Donovan, M. A. Pericak-Vance, R.
- Mayeux, J. L. Haines, L. A. Farrer, G. D. Schellenberg, P. Heutink, A. B. Singleton, A. Brice, N. W. Wood, J. Hardy,
 M. Martinez, S. H. Choi, A. DeStefano, M. A. Ikram, J. C. Bis, A. Smith, A. L. Fitzpatrick, L. Launer, C. Van Duijn,
- M. Martinez, S. H. Choi, A. DeStefano, M. A. Ikram, J. C. Bis, A. Smith, A. L. Fitzpatrick, L. Launer, C. Van Duijn,
 S. Seshadri, I. D. Ulstein, D. Aarsland, T. Fladby, S. Djurovic, B. T. Hyman, J. Snaedal, H. Stefansson, K.
- S. Sesnadri, I. D. Olstein, D. Aarstand, I. Fladdy, S. Djurovic, B. I. Hyman, J. Snaedal, H. Stefansson, K.
 Stefansson, T. Gasser, O. A. Andreassen, A. M. Dale, for the ADNI ADGC, GERAD, CHARGE and IPDGC
- 971 Stefansson, T. Gasser, O. A. Andreassen, A. M. Dare, for the ADNI ADGC, GERAD, CHARGE and IPDGC
 972 Investigators, Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. *Mol* 973 *Psychiatry* 20, 1588–1595 (2015).
- 44. E. M. Weeks, J. C. Ulirsch, N. Y. Cheng, B. L. Trippe, R. S. Fine, J. Miao, T. A. Patwardhan, M. Kanai, J.
- 975 Nasser, C. P. Fulco, K. C. Tashman, F. Aguet, T. Li, J. Ordovas-Montanes, C. S. Smillie, M. Biton, A. K. Shalek, A.
- 976 N. Ananthakrishnan, R. J. Xavier, A. Regev, R. M. Gupta, K. Lage, K. G. Ardlie, J. N. Hirschhorn, E. S. Lander, J. M. Engreiz, H. K. Einnenen, Levenging applyantia antichments of same factors to an distance of the same factors of the same fac
- M. Engreitz, H. K. Finucane, Leveraging polygenic enrichments of gene features to predict genes underlying
 complex traits and diseases. *Nat Genet* 55, 1267–1276 (2023).
- 45. Z. Sha, D. Schijven, S. E. Fisher, C. Francks, Genetic architecture of the white matter connectome of the
 human brain. *SCIENCE ADVANCES* (2023).
- 46. Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **57**, 289–300 (1995).
- Y. Wu, K. S. Burch, A. Ganna, P. Pajukanta, B. Pasaniuc, S. Sankararaman, Fast estimation of genetic correlation for biobank-scale data. *The American Journal of Human Genetics* 109, 24–32 (2022).
- 985 48. C. Palmer, I. Pe'er, Statistical correction of the Winner's Curse explains replication variability in
- 986 quantitative trait genome-wide association studies. *PLoS Genet* **13**, e1006916 (2017).
- 987 49. D. van der Meer, J. Rokicki, T. Kaufmann, A. Córdova-Palomera, T. Moberget, D. Alnæs, F. Bettella, O.
- 988 Frei, N. T. Doan, I. E. Sønderby, O. B. Smeland, I. Agartz, A. Bertolino, J. Bralten, C. L. Brandt, J. K. Buitelaar, S.
- 989 Djurovic, M. van Donkelaar, E. S. Dørum, T. Espeseth, S. V. Faraone, G. Fernández, S. E. Fisher, B. Franke, B.
- 990 Haatveit, C. A. Hartman, P. J. Hoekstra, A. K. Håberg, E. G. Jönsson, K. K. Kolskår, S. Le Hellard, M. J. Lund, A. J.
- 991 Lundervold, A. Lundervold, I. Melle, J. Monereo Sánchez, L. C. Norbom, J. E. Nordvik, L. Nyberg, J. Oosterlaan, M.
- 992 Papalino, A. Papassotiropoulos, G. Pergola, D. J. F. de Quervain, G. Richard, A.-M. Sanders, P. Selvaggi, E.

993 Shumskaya, V. M. Steen, S. Tønnesen, K. M. Ulrichsen, M. P. Zwiers, O. A. Andreassen, L. T. Westlye, Brain scans 994 from 21,297 individuals reveal the genetic architecture of hippocampal subfield volumes. Mol Psychiatry 25, 3053-995 3065 (2020). 996 M. Lanfranchi, S. Yandiev, G. Mever-Dilhet, S. Ellouze, M. Kerkhofs, R. Dos Reis, A. Garcia, C. Blondet, 50. 997 A. Amar, A. Kneppers, H. Polvèche, D. Plassard, M. Foretz, B. Viollet, K. Sakamoto, R. Mounier, C. F. Bourgeois, 998 O. Raineteau, E. Goillot, J. Courchet, The AMPK-related kinase NUAK1 controls cortical axons branching by locally 999 modulating mitochondrial metabolic functions. Nat Commun 15, 2487 (2024). C. Makowski, H. Wang, A. Srinivasan, A. Qi, Y. Qiu, D. van der Meer, O. Frei, J. Zou, P. M. Visscher, J. 1000 51. Yang, C.-H. Chen, Larger cerebral cortex is genetically correlated with greater frontal area and dorsal thickness. 1001 Proceedings of the National Academy of Sciences 120, e2214834120 (2023). 1002 1003 A. Okbay, Y. Wu, N. Wang, H. Jayashankar, M. Bennett, S. M. Nehzati, J. Sidorenko, H. Kweon, G. 52. 1004 Goldman, T. Gjorgjieva, Y. Jiang, B. Hicks, C. Tian, D. A. Hinds, R. Ahlskog, P. K. E. Magnusson, S. Oskarsson, C. 1005 Hayward, A. Campbell, D. J. Porteous, J. Freese, P. Herd, C. Watson, J. Jala, D. Conley, P. D. Koellinger, M. Johannesson, D. Laibson, M. N. Meyer, J. J. Lee, A. Kong, L. Yengo, D. Cesarini, P. Turley, P. M. Visscher, J. P. 1006 1007 Beauchamp, D. J. Benjamin, A. I. Young, Polygenic prediction of educational attainment within and between 1008 families from genome-wide association analyses in 3 million individuals. Nat Genet 54, 437-449 (2022). 1009 M. P. M. Soutar, D. Melandri, B. O'Callaghan, E. Annuario, A. E. Monaghan, N. J. Welsh, K. D'Sa, S. 53. 1010 Guelfi, D. Zhang, A. Pittman, D. Trabzuni, A. H. A. Verboven, K. S. Pan, D. A. Kia, M. Bictash, S. Gandhi, H. 1011 Houlden, M. R. Cookson, N. N. Kasri, N. W. Wood, A. B. Singleton, J. Hardy, P. J. Whiting, C. Blauwendraat, A. J. 1012 Whitworth, C. Manzoni, M. Ryten, P. A. Lewis, H. Plun-Favreau, Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson's disease at 16q11.2 and MAPT H1 loci. Brain 145, 4349-4367 (2022). 1013 M. Baker, I. Litvan, H. Houlden, J. Adamson, D. Dickson, J. Perez-Tur, J. Hardy, T. Lynch, E. Bigio, M. 1014 54. 1015 Hutton, Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy. Human 1016 *Molecular Genetics* **8**, 711–715 (1999). A. M. Pittman, The structure of the tau haplotype in controls and in progressive supranuclear palsy. Human 1017 55. 1018 Molecular Genetics 13, 1267–1274 (2004). 56. 1019 A. M. Pittman, A. J. Myers, P. Abou-Sleiman, H. C. Fung, M. Kaleem, L. Marlowe, J. Duckworth, D. Leung, D. Williams, L. Kilford, N. Thomas, C. M. Morris, D. Dickson, N. W. Wood, J. Hardy, A. J. Lees, R. de 1020 1021 Silva, Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive 1022 supranuclear palsy and corticobasal degeneration. Journal of Medical Genetics 42, 837-846 (2005). P. Pastor, M. Ezquerra, J. C. Perez, S. Chakraverty, J. Norton, B. A. Racette, D. McKeel, J. S. Perlmutter, E. 1023 57. 1024 Tolosa, A. M. Goate, Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Annals of 1025 Neurology 56, 249–258 (2004). 1026 M. G. Spillantini, J. R. Murrell, M. Goedert, M. R. Farlow, A. Klug, B. Ghetti, Mutation in the tau gene in 58. 1027 familial multiple system tauopathy with presentile dementia. Proceedings of the National Academy of Sciences 95, 1028 7737–7741 (1998). J. Simón-Sánchez, C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs, D. Berg, C. Paisan-Ruiz, P. Lichtner, S. 1029 59. W. Scholz, D. G. Hernandez, R. Krüger, M. Federoff, C. Klein, A. Goate, J. Perlmutter, M. Bonin, M. A. Nalls, T. 1030 Illig, C. Gieger, H. Houlden, M. Steffens, M. S. Okun, B. A. Racette, M. R. Cookson, K. D. Foote, H. H. Fernandez, 1031 1032 B. J. Travnor, S. Schreiber, S. Arepalli, R. Zonozi, K. Gwinn, M. van der Brug, G. Lopez, S. J. Chanock, A. 1033 Schatzkin, Y. Park, A. Hollenbeck, J. Gao, X. Huang, N. W. Wood, D. Lorenz, G. Deuschl, H. Chen, O. Riess, J. A. 1034 Hardy, A. B. Singleton, T. Gasser, Genome-wide association study reveals genetic risk underlying Parkinson's 1035 disease. Nat Genet 41, 1308-1312 (2009). 1036 P. Sánchez-Juan, S. Moreno, I. de Rojas, I. Hernández, S. Valero, M. Alegret, L. Montrreal, P. García 60. 1037 González, C. Lage, S. López-García, E. Rodríguez-Rodríguez, A. Orellana, L. Tárraga, M. Boada, A. Ruiz, The 1038 MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE &4 Non-carriers. Front Aging Neurosci 11, 1039 327 (2019). 1040 N. Kouri, O. A. Ross, B. Dombroski, C. S. Younkin, D. J. Serie, A. Soto-Ortolaza, M. Baker, N. C. A. 61. 1041 Finch, H. Yoon, J. Kim, S. Fujioka, C. A. McLean, B. Ghetti, S. Spina, L. B. Cantwell, M. R. Farlow, J. Grafman, E. D. Huey, M. Ryung Han, S. Beecher, E. T. Geller, H. A. Kretzschmar, S. Roeber, M. Gearing, J. L. Juncos, J. P. G. 1042 1043 Vonsattel, V. M. Van Deerlin, M. Grossman, H. I. Hurtig, R. G. Gross, S. E. Arnold, J. O. Trojanowski, V. M. Lee, 1044 G. K. Wenning, C. L. White, G. U. Höglinger, U. Müller, B. Devlin, L. I. Golbe, J. Crook, J. E. Parisi, B. F. Boeve, 1045 K. A. Josephs, Z. K. Wszolek, R. J. Uitti, N. R. Graff-Radford, I. Litvan, S. G. Younkin, L.-S. Wang, N. Ertekin-Taner, R. Rademakers, H. Hakonarsen, G. D. Schellenberg, D. W. Dickson, Genome-wide association study of 1046 corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 6, 7247 1047 1048 (2015). 1049 62. C. Bellenguez, F. Kücükali, I. E. Jansen, L. Kleineidam, S. Moreno-Grau, N. Amin, A. C. Naj, R. Campos-1050 Martin, B. Grenier-Boley, V. Andrade, P. A. Holmans, A. Boland, V. Damotte, S. J. van der Lee, M. R. Costa, T. Kuulasmaa, Q. Yang, I. de Rojas, J. C. Bis, A. Yaqub, I. Prokic, J. Chapuis, S. Ahmad, V. Giedraitis, D. Aarsland, P. 1051 1052 Garcia-Gonzalez, C. Abdelnour, E. Alarcón-Martín, D. Alcolea, M. Alegret, I. Alvarez, V. Álvarez, N. J. Armstrong, 1053 A. Tsolaki, C. Antúnez, I. Appollonio, M. Arcaro, S. Archetti, A. A. Pastor, B. Arosio, L. Athanasiu, H. Bailly, N.

1054 Banaj, M. Baquero, S. Barral, A. Beiser, A. B. Pastor, J. E. Below, P. Benchek, L. Benussi, C. Berr, C. Besse, V. 1055 Bessi, G. Binetti, A. Bizarro, R. Blesa, M. Boada, E. Boerwinkle, B. Borroni, S. Boschi, P. Bossù, G. Bråthen, J. 1056 Bressler, C. Bresner, H. Brodaty, K. J. Brookes, L. I. Brusco, D. Buiza-Rueda, K. Bûrger, V. Burholt, W. S. Bush, M. Calero, L. B. Cantwell, G. Chene, J. Chung, M. L. Cuccaro, Á. Carracedo, R. Cecchetti, L. Cervera-Carles, C. 1057 Charbonnier, H.-H. Chen, C. Chillotti, S. Ciccone, J. A. H. R. Claassen, C. Clark, E. Conti, A. Corma-Gómez, E. 1058 Costantini, C. Custodero, D. Daian, M. C. Dalmasso, A. Daniele, E. Dardiotis, J.-F. Dartigues, P. P. de Devn, K. de 1059 1060 Paiva Lopes, L. D. de Witte, S. Debette, J. Deckert, T. del Ser, N. Denning, A. DeStefano, M. Dichgans, J. Diehl-Schmid, M. Diez-Fairen, P. D. Rossi, S. Djurovic, E. Duron, E. Düzel, C. Dufouil, G. Eiriksdottir, S. Engelborghs, V. 1061 Escott-Price, A. Espinosa, M. Ewers, K. M. Faber, T. Fabrizio, S. F. Nielsen, D. W. Fardo, L. Farotti, C. Fenoglio, 1062 M. Fernández-Fuertes, R. Ferrari, C. B. Ferreira, E. Ferri, B. Fin, P. Fischer, T. Fladby, K. Fließbach, B. Fongang, M. 1063 1064 Fornage, J. Fortea, T. M. Foroud, S. Fostinelli, N. C. Fox, E. Franco-Macías, M. J. Bullido, A. Frank-García, L. 1065 Froelich, B. Fulton-Howard, D. Galimberti, J. M. García-Alberca, P. García-González, S. Garcia-Madrona, G. 1066 Garcia-Ribas, R. Ghidoni, I. Giegling, G. Giorgio, A. M. Goate, O. Goldhardt, D. Gomez-Fonseca, A. González-Pérez, C. Graff, G. Grande, E. Green, T. Grimmer, E. Grünblatt, M. Grunin, V. Gudnason, T. Guetta-Baranes, A. 1067 1068 Haapasalo, G. Hadjigeorgiou, J. L. Haines, K. L. Hamilton-Nelson, H. Hampel, O. Hanon, J. Hardy, A. M. 1069 Hartmann, L. Hausner, J. Harwood, S. Heilmann-Heimbach, S. Helisalmi, M. T. Heneka, I. Hernández, M. J. 1070 Herrmann, P. Hoffmann, C. Holmes, H. Holstege, R. H. Vilas, M. Hulsman, J. Humphrey, G. J. Biessels, X. Jian, C. 1071 Johansson, G. R. Jun, Y. Kastumata, J. Kauwe, P. G. Kehoe, L. Kilander, A. K. Ståhlbom, M. Kivipelto, A. Koivisto, 1072 J. Kornhuber, M. H. Kosmidis, W. A. Kukull, P. P. Kuksa, B. W. Kunkle, A. B. Kuzma, C. Lage, E. J. Laukka, L. 1073 Launer, A. Lauria, C.-Y. Lee, J. Lehtisalo, O. Lerch, A. Lleó, W. Longstreth, O. Lopez, A. L. de Munain, S. Love, M. Löwemark, L. Luckcuck, K. L. Lunetta, Y. Ma, J. Macías, C. A. MacLeod, W. Maier, F. Mangialasche, M. 1074 1075 Spallazzi, M. Marquié, R. Marshall, E. R. Martin, A. M. Montes, C. M. Rodríguez, C. Masullo, R. Mayeux, S. Mead, 1076 P. Mecocci, M. Medina, A. Meggy, S. Mehrabian, S. Mendoza, M. Menéndez-González, P. Mir, S. Moebus, M. Mol, 1077 L. Molina-Porcel, L. Montrreal, L. Morelli, F. Moreno, K. Morgan, T. Mosley, M. M. Nöthen, C. Muchnik, S. Mukherjee, B. Nacmias, T. Ngandu, G. Nicolas, B. G. Nordestgaard, R. Olaso, A. Orellana, M. Orsini, G. Ortega, A. 1078 1079 Padovani, C. Paolo, G. Papenberg, L. Parnetti, F. Pasquier, P. Pastor, G. Peloso, A. Pérez-Cordón, J. Pérez-Tur, P. 1080 Pericard, O. Peters, Y. A. L. Pijnenburg, J. A. Pineda, G. Piñol-Ripoll, C. Pisanu, T. Polak, J. Popp, D. Posthuma, J. Priller, R. Puerta, O. Quenez, I. Quintela, J. Q. Thomassen, A. Rábano, I. Rainero, F. Rajabli, I. Ramakers, L. M. 1081 1082 Real, M. J. T. Reinders, C. Reitz, D. Reves-Dumever, P. Ridge, S. Riedel-Heller, P. Riederer, N. Roberto, E. 1083 Rodriguez-Rodriguez, A. Rongve, I. R. Allende, M. Rosende-Roca, J. L. Royo, E. Rubino, D. Rujescu, M. E. Sáez, P. Sakka, I. Saltvedt, Á. Sanabria, M. B. Sánchez-Arjona, F. Sanchez-Garcia, P. S. Juan, R. Sánchez-Valle, S. B. 1084 1085 Sando, C. Sarnowski, C. L. Satizabal, M. Scamosci, N. Scarmeas, E. Scarpini, P. Scheltens, N. Scherbaum, M. 1086 Scherer, M. Schmid, A. Schneider, J. M. Schott, G. Selbæk, D. Seripa, M. Serrano, J. Sha, A. A. Shadrin, O. Skrobot, S. Slifer, G. J. L. Snijders, H. Soininen, V. Solfrizzi, A. Solomon, Y. Song, S. Sorbi, O. Sotolongo-Grau, G. Spalletta, 1087 1088 A. Spottke, A. Squassina, E. Stordal, J. P. Tartan, L. Tárraga, N. Tesí, A. Thalamuthu, T. Thomas, G. Tosto, L. Travkov, L. Tremolizzo, A. Tybjærg-Hansen, A. Uitterlinden, A. Ullgren, I. Ulstein, S. Valero, O. Valladares, C. V. 1089 Broeckhoven, J. Vance, B. N. Vardarajan, A. van der Lugt, J. V. Dongen, J. van Rooij, J. van Swieten, R. 1090 1091 Vandenberghe, F. Verhey, J.-S. Vidal, J. Vogelgsang, M. Vyhnalek, M. Wagner, D. Wallon, L.-S. Wang, R. Wang, 1092 L. Weinhold, J. Wiltfang, G. Windle, B. Woods, M. Yannakoulia, H. Zare, Y. Zhao, X. Zhang, C. Zhu, M. Zulaica, 1093 L. A. Farrer, B. M. Psaty, M. Ghanbari, T. Rai, P. Sachdev, K. Mather, F. Jessen, M. A. Ikram, A. de Mendonca, J. 1094 Hort, M. Tsolaki, M. A. Pericak-Vance, P. Amouyel, J. Williams, R. Frikke-Schmidt, J. Clarimon, J.-F. Deleuze, G. 1095 Rossi, S. Seshadri, O. A. Andreassen, M. Ingelsson, M. Hiltunen, K. Sleegers, G. D. Schellenberg, C. M. van Duijn, 1096 R. Sims, W. M. van der Flier, A. Ruiz, A. Ramirez, J.-C. Lambert, New insights into the genetic etiology of 1097 Alzheimer's disease and related dementias. Nat Genet 54, 412-436 (2022). 1098 W. Huang, J. Zeng, L. Jia, D. Zhu, J. O'Brien, C. Ritchie, N. Shu, L. Su, Genetic risks of Alzheimer's by 63. 1099 APOE and MAPT on cortical morphology in young healthy adults. Brain Commun 5, fcad234 (2023). 1100 64. J. H. Lee, J. Ryan, C. Andreescu, H. Aizenstein, H. K. Lim, Brainstem morphological changes in 1101 Alzheimer's disease. Neuroreport 26, 411–415 (2015). P. Theofilas, A. J. Ehrenberg, S. Dunlop, A. T. Alho, A. Nguy, R. E. P. Leite, R. D. Rodriguez, M. B. Mejia, 1102 65. C. K. Suemoto, R. E. de Lucena Ferretti-Rebustini, L. Polichiso, C. F. Nascimento, W. W. Seeley, R. Nitrini, C. A. 1103 1104 Pasqualucci, W. J. Filho, U. Rueb, J. Neuhaus, H. Heinsen, L. T. Grinberg, Locus coeruleus volume and cell 1105 population changes during Alzheimer's disease progression: a stereological study in human postmortem brains with 1106 potential implication for early-stage biomarker discovery. Alzheimers Dement 13, 236-246 (2017). A. J. Ehrenberg, C. K. Suemoto, E. de Paula França Resende, C. Petersen, R. E. P. Leite, R. D. Rodriguez, 1107 66. R. E. de Lucena Ferretti-Rebustini, M. You, J. Oh, R. Nitrini, C. A. Pasqualucci, W. Jacob-Filho, J. H. Kramer, J. R. 1108 1109 Gatchel, L. T. Grinberg, Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. J Alzheimers 1110 Dis 66, 115–126 (2018). 1111 D. A. Koolen, R. Pfundt, K. Linda, G. Beunders, H. E. Veenstra-Knol, J. H. Conta, A. M. Fortuna, G. 67. Gillessen-Kaesbach, S. Dugan, S. Halbach, O. A. Abdul-Rahman, H. M. Winesett, W. K. Chung, M. Dalton, P. S. 1112 1113 Dimova, T. Mattina, K. Prescott, H. Z. Zhang, H. M. Saal, J. Y. Hehir-Kwa, M. H. Willemsen, C. W. Ockeloen, M. 1114 C. Jongmans, N. Van der Aa, P. Failla, C. Barone, E. Avola, A. S. Brooks, S. G. Kant, E. H. Gerkes, H. V. Firth, K.

1115 Õunap, L. M. Bird, D. Masser-Frye, J. R. Friedman, M. A. Sokunbi, A. Dixit, M. Splitt, M. K. Kukolich, J. 1116 McGaughran, B. P. Coe, J. Flórez, N. Nadif Kasri, H. G. Brunner, E. M. Thompson, J. Gecz, C. Romano, E. E. 1117 Eichler, B. B. de Vries, The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant. Eur J Hum Genet 24, 652–659 (2016). 1118 J. Xu, N. Liu, E. Polemiti, L. Garcia-Mondragon, J. Tang, X. Liu, T. Lett, L. Yu, M. M. Nöthen, J. Feng, C. 1119 68. 1120 Yu, A. Marquand, G. Schumann, Effects of urban living environments on mental health in adults. Nat Med 29, 1456– 1121 1467 (2023). 1122 69. A. C. H. Chen, N. Manz, Y. Tang, M. Rangaswamy, L. Almasy, S. Kuperman, J. Nurnberger Jr, S. J. O'Connor, H. J. Edenberg, M. A. Schuckit, J. Tischfield, T. Foroud, L. J. Bierut, J. Rohrbaugh, J. P. Rice, A. Goate, 1123 V. Hesselbrock, B. Porjesz, Single-Nucleotide Polymorphisms in Corticotropin Releasing Hormone Receptor 1 Gene 1124 (CRHR1) Are Associated With Quantitative Trait of Event-Related Potential and Alcohol Dependence. Alcoholism: 1125 1126 Clinical and Experimental Research 34, 988–996 (2010). D. Blomeyer, J. Treutlein, G. Esser, M. H. Schmidt, G. Schumann, M. Laucht, Interaction between CRHR1 1127 70. Gene and Stressful Life Events Predicts Adolescent Heavy Alcohol Use. Biological Psychiatry 63, 146–151 (2008). 1128 1129 71. R. Daviet, G. Aydogan, K. Jagannathan, N. Spilka, P. D. Koellinger, H. R. Kranzler, G. Nave, R. R. 1130 Wetherill, Associations between alcohol consumption and gray and white matter volumes in the UK Biobank. Nat 1131 Commun 13, 1175 (2022). A. Thompson, J. Cook, H. Choquet, E. Jorgenson, J. Yin, T. Kinnunen, J. Barclay, A. P. Morris, M. 1132 72. 1133 Pirmohamed, Functional validity, role, and implications of heavy alcohol consumption genetic loci. Sci Adv 6, 1134 eaay5034 (2020). T. Chambers, V. Escott-Price, S. Legge, E. Baker, K. D. Singh, J. T. R. Walters, X. Caseras, R. J. L. Anney, 1135 73. Genetic common variants associated with cerebellar volume and their overlap with mental disorders: a study on 1136 1137 33,265 individuals from the UK-Biobank. Mol Psychiatry 27, 2282–2290 (2022). 1138 74. N. C. Andreasen, R. Pierson, The Role of the Cerebellum in Schizophrenia. Biol Psychiatry 64, 81-88 1139 (2008).T. G. M. van Erp, D. P. Hibar, J. M. Rasmussen, D. C. Glahn, G. D. Pearlson, O. A. Andreassen, I. Agartz, 1140 75. 1141 L. T. Westlye, U. K. Haukvik, A. M. Dale, I. Melle, C. B. Hartberg, O. Gruber, B. Kraemer, D. Zilles, G. Donohoe, S. Kelly, C. McDonald, D. W. Morris, D. M. Cannon, A. Corvin, M. W. J. Machielsen, L. Koenders, L. de Haan, D. 1142 1143 J. Veltman, T. D. Satterthwaite, D. H. Wolf, R. C. Gur, R. E. Gur, S. G. Potkin, D. H. Mathalon, B. A. Mueller, A. 1144 Preda, F. Macciardi, S. Ehrlich, E. Walton, J. Hass, V. D. Calhoun, H. J. Bockholt, S. R. Sponheim, J. M. Shoemaker, 1145 N. E. M. van Haren, H. E. H. Pol, R. A. Ophoff, R. S. Kahn, R. Roiz-Santiañez, B. Crespo-Facorro, L. Wang, K. I. 1146 Alpert, E. G. Jönsson, R. Dimitrova, C. Bois, H. C. Whalley, A. M. McIntosh, S. M. Lawrie, R. Hashimoto, P. M. 1147 Thompson, J. A. Turner, Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 1148 healthy controls via the ENIGMA consortium. Mol Psychiatry 21, 547-553 (2016). 1149 N. Okada, M. Fukunaga, K. Miura, K. Nemoto, J. Matsumoto, N. Hashimoto, M. Kiyota, K. Morita, D. 76. Koshiyama, K. Ohi, T. Takahashi, M. Koeda, H. Yamamori, M. Fujimoto, Y. Yasuda, N. Hasegawa, H. Narita, S. 1150 Yokoyama, R. Mishima, T. Kawashima, Y. Kobayashi, D. Sasabayashi, K. Harada, M. Yamamoto, Y. Hirano, T. 1151 Itahashi, M. Nakataki, R. Hashimoto, K. K. Tha, S. Koike, T. Matsubara, G. Okada, T. G. M. van Erp, N. Jahanshad, 1152 R. Yoshimura, O. Abe, T. Onitsuka, Y. Watanabe, K. Matsuo, H. Yamasue, Y. Okamoto, M. Suzuki, J. A. Turner, P. 1153 1154 M. Thompson, N. Ozaki, K. Kasai, R. Hashimoto, Subcortical volumetric alterations in four major psychiatric 1155 disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification. Mol 1156 Psychiatry, 1–11 (2023). Y. Jiang, C. Luo, J. Wang, L. Palaniyappan, X. Chang, S. Xiang, J. Zhang, M. Duan, H. Huang, C. Gaser, K. 1157 77. 1158 Nemoto, K. Miura, R. Hashimoto, L. T. Westlye, G. Richard, S. Fernandez-Cabello, N. Parker, O. A. Andreassen, T. 1159 Kircher, I. Nenadić, F. Stein, F. Thomas-Odenthal, L. Teutenberg, P. Usemann, U. Dannlowski, T. Hahn, D. 1160 Grotegerd, S. Meinert, R. Lencer, Y. Tang, T. Zhang, C. Li, W. Yue, Y. Zhang, X. Yu, E. Zhou, C.-P. Lin, S.-J. Tsai, 1161 A. L. Rodrigue, D. Glahn, G. Pearlson, J. Blangero, A. Karuk, E. Pomarol-Clotet, R. Salvador, P. Fuentes-Claramonte, M. Á. Garcia-León, G. Spalletta, F. Piras, D. Vecchio, N. Banaj, J. Cheng, Z. Liu, J. Yang, A. S. Gonul, 1162 O. Uslu, B. B. Burhanoglu, A. U. Demir, K. Rootes-Murdy, V. D. Calhoun, K. Sim, M. Green, Y. Quidé, Y. C. 1163 Chung, W.-S. Kim, S. R. Sponheim, C. Demro, I. S. Ramsay, F. Iasevoli, A. de Bartolomeis, A. Barone, M. 1164 1165 Ciccarelli, A. Brunetti, S. Cocozza, G. Pontillo, M. Tranfa, M. T. M. Park, M. Kirschner, F. Georgiadis, S. Kaiser, T. 1166 E. V. Rheenen, S. L. Rossell, M. Hughes, W. Woods, S. P. Carruthers, P. Sumner, E. Ringin, F. Spaniel, A. Skoch, D. Tomecek, P. Homan, S. Homan, W. Omlor, G. Cecere, D. D. Nguyen, A. Preda, S. Thomopoulos, N. Jahanshad, 1167 L.-B. Cui, D. Yao, P. M. Thompson, J. A. Turner, T. G. M. van Erp, W. Cheng, J. Feng, Two neurostructural 1168 subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia. medRxiv, 1169 1170 2023.10.11.23296862 (2023). 1171 78. J. R. Glausier, D. A. Lewis, Dendritic spine pathology in schizophrenia. *Neuroscience* 251, 90–107 (2013). 1172 79. S. Li, C. Ma, Y. Li, R. Chen, Y. Liu, L. P. Wan, Q. Xiong, C. Wang, Y. Huo, X. Dang, Y. Yang, L. Lv, X. Chen, N. Sheng, W. Li, X.-J. Luo, The schizophrenia-associated missense variant rs13107325 regulates dendritic 1173 spine density. Transl Psychiatry 12, 1-12 (2022). 1174 1175 80. E.-M. Stauffer, R. A. I. Bethlehem, L. Dorfschmidt, H. Won, V. Warrier, E. T. Bullmore, The genetic

1176 relationships between brain structure and schizophrenia. Nat Commun 14, 7820 (2023). 1177 81. S. H. Lee, S. Ripke, B. M. Neale, S. V. Faraone, S. M. Purcell, R. H. Perlis, B. J. Mowry, A. Thapar, M. E. 1178 Goddard, J. S. Witte, D. Absher, I. Agartz, H. Akil, F. Amin, O. A. Andreassen, A. Anjorin, R. Anney, V. Anttila, D. E. Arking, P. Asherson, M. H. Azevedo, L. Backlund, J. A. Badner, A. J. Bailey, T. Banaschewski, J. D. Barchas, M. 1179 R. Barnes, T. B. Barrett, N. Bass, A. Battaglia, M. Bauer, M. Bayés, F. Bellivier, S. E. Bergen, W. Berrettini, C. 1180 1181 Betancur, T. Bettecken, J. Biederman, E. B. Binder, D. W. Black, D. H. R. Blackwood, C. S. Bloss, M. Boehnke, D. I. Boomsma, G. Breen, R. Breuer, R. Bruggeman, P. Cormican, N. G. Buccola, J. K. Buitelaar, W. E. Bunney, J. D. 1182 Buxbaum, W. F. Byerley, E. M. Byrne, S. Caesar, W. Cahn, R. M. Cantor, M. Casas, A. Chakravarti, K. Chambert, 1183 1184 K. Choudhury, S. Cichon, C. R. Cloninger, D. A. Collier, E. H. Cook, H. Coon, B. Cormand, A. Corvin, W. H. Coryell, D. W. Craig, I. W. Craig, J. Crosbie, M. L. Cuccaro, D. Curtis, D. Czamara, S. Datta, G. Dawson, R. Day, E. 1185 1186 J. De Geus, F. Degenhardt, S. Djurovic, G. J. Donohoe, A. E. Doyle, J. Duan, F. Dudbridge, E. Duketis, R. P. 1187 Ebstein, H. J. Edenberg, J. Elia, S. Ennis, B. Etain, A. Fanous, A. E. Farmer, I. N. Ferrier, M. Flickinger, E. 1188 Fombonne, T. Foroud, J. Frank, B. Franke, C. Fraser, R. Freedman, N. B. Freimer, C. M. Freitag, M. Friedl, L. 1189 Frisén, L. Gallagher, P. V. Gejman, L. Georgieva, E. S. Gershon, D. H. Geschwind, I. Giegling, M. Gill, S. D. 1190 Gordon, K. Gordon-Smith, E. K. Green, T. A. Greenwood, D. E. Grice, M. Gross, D. Grozeva, W. Guan, H. Gurling, 1191 L. De Haan, J. L. Haines, H. Hakonarson, J. Hallmayer, S. P. Hamilton, M. L. Hamshere, T. F. Hansen, A. M. 1192 Hartmann, M. Hautzinger, A. C. Heath, A. K. Henders, S. Herms, I. B. Hickie, M. Hipolito, S. Hoefels, P. A. 1193 Holmans, F. Holsboer, W. J. Hoogendijk, J.-J. Hottenga, C. M. Hultman, V. Hus, A. Ingason, M. Ising, S. Jamain, E. 1194 G. Jones, I. Jones, L. Jones, J.-Y. Tzeng, A. K. Kähler, R. S. Kahn, R. Kandaswamy, M. C. Keller, J. L. Kennedy, E. 1195 Kenny, L. Kent, Y. Kim, G. K. Kirov, S. M. Klauck, L. Klei, J. A. Knowles, M. A. Kohli, D. L. Koller, B. Konte, A. 1196 Korszun, L. Krabbendam, R. Krasucki, J. Kuntsi, P. Kwan, M. Landén, N. Långström, M. Lathrop, J. Lawrence, W. B. Lawson, M. Leboyer, D. H. Ledbetter, P. H. Lee, T. Lencz, K.-P. Lesch, D. F. Levinson, C. M. Lewis, J. Li, P. 1197 1198 Lichtenstein, J. A. Lieberman, D.-Y. Lin, D. H. Linszen, C. Liu, F. W. Lohoff, S. K. Loo, C. Lord, J. K. Lowe, S. 1199 Lucae, D. J. MacIntvre, P. A. F. Madden, E. Maestrini, P. K. E. Magnusson, P. B. Mahon, W. Maier, A. K. Malhotra, 1200 S. M. Mane, C. L. Martin, N. G. Martin, M. Mattheisen, K. Matthews, M. Mattingsdal, S. A. McCarroll, K. A. 1201 McGhee, J. J. McGough, P. J. McGrath, P. McGuffin, M. G. McInnis, A. McIntosh, R. McKinnev, A. W. McLean, F. 1202 J. McMahon, W. M. McMahon, A. McQuillin, H. Medeiros, S. E. Medland, S. Meier, I. Melle, F. Meng, J. Meyer, C. M. Middeldorp, L. Middleton, V. Milanova, A. Miranda, A. P. Monaco, G. W. Montgomery, J. L. Moran, D. 1203 1204 Moreno-De-Luca, G. Morken, D. W. Morris, E. M. Morrow, V. Moskvina, P. Muglia, T. W. Mühleisen, W. J. Muir, 1205 B. Müller-Myhsok, M. Murtha, R. M. Myers, I. Myin-Germeys, M. C. Neale, S. F. Nelson, C. M. Nievergelt, I. 1206 Nikolov, V. Nimgaonkar, W. A. Nolen, M. M. Nöthen, J. I. Nurnberger, E. A. Nwulia, D. R. Nyholt, C. O'Dushlaine, 1207 R. D. Oades, A. Olincy, G. Oliveira, L. Olsen, R. A. Ophoff, U. Osby, M. J. Owen, A. Palotie, J. R. Parr, A. D. 1208 Paterson, C. N. Pato, M. T. Pato, B. W. Penninx, M. L. Pergadia, M. A. Pericak-Vance, B. S. Pickard, J. Pimm, J. 1209 Piven, D. Posthuma, J. B. Potash, F. Poustka, P. Propping, V. Puri, D. J. Quested, E. M. Quinn, J. A. Ramos-Quiroga, 1210 H. B. Rasmussen, S. Ravchaudhuri, K. Rehnström, A. Reif, M. Ribasés, J. P. Rice, M. Rietschel, K. Roeder, H. 1211 Roevers, L. Rossin, A. Rothenberger, G. Rouleau, D. Ruderfer, D. Rujescu, A. R. Sanders, S. J. Sanders, S. L. 1212 Santangelo, J. A. Sergeant, R. Schachar, M. Schalling, Cross-Disorder Group of the Psychiatric Genomics Consortium, Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 1213 45, 984-994 (2013). 1214 1215 82. M. Madre, E. J. Canales-Rodríguez, P. Fuentes-Claramonte, S. Alonso-Lana, P. Salgado-Pineda, A. 1216 Guerrero-Pedraza, N. Moro, C. Bosque, J. J. Gomar, J. Ortíz-Gil, J. M. Goikolea, C. M. Bonnin, E. Vieta, S. Sarró, T. 1217 Maristany, P. J. McKenna, R. Salvador, E. Pomarol-Clotet, Structural abnormality in schizophrenia versus bipolar 1218 disorder: A whole brain cortical thickness, surface area, volume and gyrification analyses. NeuroImage: Clinical 25, 1219 102131 (2020). 1220 83. M. Canavan, M. J. O'Donnell, Hypertension and Cognitive Impairment: A Review of Mechanisms and Key 1221 Concepts. Front Neurol 13, 821135 (2022). 1222 84. L. M. Jenkins, C. R. Garner, S. Kurian, J. P. Higgins, T. B. Parrish, S. Sedaghat, A. J. Nemeth, D. M. Lloyd-1223 Jones, L. J. Launer, J. M. Hausdorff, L. Wang, F. A. Sorond, Cumulative Blood Pressure Exposure, Basal Ganglia, 1224 and Thalamic Morphology in Midlife. Hypertension 75, 1289-1295 (2020). Y. Halchenko, K. Meyer, B. Poldrack, D. Solanky, A. Wagner, J. Gors, D. MacFarlane, D. Pustina, V. 1225 85. 1226 Sochat, S. Ghosh, C. Mönch, C. Markiewicz, L. Waite, I. Shlyakhter, A. De La Vega, S. Hayashi, C. Häusler, J.-B. 1227 Poline, T. Kadelka, K. Skytén, D. Jarecka, D. Kennedy, T. Strauss, M. Cieslak, P. Vavra, H.-I. Ioanas, R. Schneider, 1228 M. Pflüger, J. Haxby, S. Eickhoff, M. Hanke, DataLad: distributed system for joint management of code, data, and 1229 their relationship. JOSS 6, 3262 (2021). 1230 C. C. Chang, C. C. Chow, L. C. Tellier, S. Vattikuti, S. M. Purcell, J. J. Lee, Second-generation PLINK: 86. 1231 rising to the challenge of larger and richer datasets. GigaSci 4, 7 (2015). 1232 C. Bycroft, C. Freeman, D. Petkova, G. Band, L. T. Elliott, K. Sharp, A. Motver, D. Vukcevic, O. Delaneau, 87. 1233 J. O'Connell, A. Cortes, S. Welsh, A. Young, M. Effingham, G. McVean, S. Leslie, N. Allen, P. Donnelly, J. 1234 Marchini, The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018). 1235 88. M. Mills, N. Barban, F. C. Tropf, An Introduction to Statistical Genetic Data Analysis (The MIT Press, 1236 Cambridge, Massachusetts London, England, 2020).

1237 89. J. Graffelman, V. Moreno, The mid p-value in exact tests for Hardy-Weinberg equilibrium. Statistical 1238 Applications in Genetics and Molecular Biology 12 (2013). 1239 90. A. M. Dale, M. I. Sereno, Improved Localizadon of Cortical Activity by Combining EEG and MEG with 1240 MRI Cortical Surface Reconstruction: A Linear Approach. Journal of Cognitive Neuroscience 5, 162–176 (1993). 1241 91. A. M. Dale, B. Fischl, M. I. Sereno, Cortical Surface-Based Analysis. *NeuroImage* 9, 179–194 (1999). 92. 1242 B. Fischl, M. I. Sereno, A. M. Dale, Cortical Surface-Based Analysis. *NeuroImage* 9, 195–207 (1999). 1243 93. B. Fischl, M. I. Sereno, R. B. H. Tootell, A. M. Dale, High-resolution intersubject averaging and a 1244 coordinate system for the cortical surface. Hum. Brain Mapp. 8, 272–284 (1999). B. Fischl, D. H. Salat, E. Busa, M. Albert, M. Dieterich, C. Haselgrove, A. van der Kouwe, R. Killiany, D. 1245 94. 1246 Kennedy, S. Klaveness, A. Montillo, N. Makris, B. Rosen, A. M. Dale, Whole Brain Segmentation: Automated 1247 Labeling of Neuroanatomical Structures in the Human Brain. Neuron 33, 341-355 (2002). 1248 95. The 1000 Genomes Project Consortium, A. Auton, G. R. Abecasis, D. M. Altshuler, R. M. Durbin, G. R. 1249 Abecasis, D. R. Bentley, A. Chakravarti, A. G. Clark, P. Donnelly, E. E. Eichler, P. Flicek, S. B. Gabriel, R. A. Gibbs, E. D. Green, M. E. Hurles, B. M. Knoppers, J. O. Korbel, E. S. Lander, C. Lee, H. Lehrach, E. R. Mardis, G. 1250 1251 T. Marth, G. A. McVean, D. A. Nickerson, J. P. Schmidt, S. T. Sherry, J. Wang, R. K. Wilson, R. A. Gibbs, E. 1252 Boerwinkle, H. Doddapaneni, Y. Han, V. Korchina, C. Kovar, S. Lee, D. Muzny, Jeffrey G. Reid, Y. Zhu, J. Wang, 1253 Y. Chang, O. Feng, X. Fang, X. Guo, M. Jian, H. Jiang, X. Jin, T. Lan, G. Li, J. Li, Y. Li, S. Liu, X. Liu, Y. Lu, X. 1254 Ma, M. Tang, B. Wang, G. Wang, H. Wu, R. Wu, X. Xu, Y. Yin, D. Zhang, W. Zhang, J. Zhao, M. Zhao, X. Zheng, 1255 E. S. Lander, D. M. Altshuler, S. B. Gabriel, N. Gupta, N. Gharani, L. H. Toji, N. P. Gerry, A. M. Resch, P. Flicek, J. 1256 Barker, L. Clarke, L. Gil, S. E. Hunt, G. Kelman, E. Kulesha, R. Leinonen, W. M. McLaren, R. Radhakrishnan, A. Roa, D. Smirnov, R. E. Smith, I. Streeter, A. Thormann, I. Toneva, B. Vaughan, X. Zheng-Bradley, D. R. Bentley, R. 1257 Grocock, S. Humphray, T. James, Z. Kingsbury, H. Lehrach, R. Sudbrak, M. W. Albrecht, V. S. Amstislavskiy, T. A. 1258 1259 Borodina, M. Lienhard, F. Mertes, M. Sultan, B. Timmermann, M.-L. Yaspo, E. R. Mardis, R. K. Wilson, L. Fulton, 1260 R. Fulton, S. T. Sherry, V. Ananiev, Z. Belaia, D. Beloslyudtsev, N. Bouk, C. Chen, D. Church, R. Cohen, C. Cook, 1261 J. Garner, T. Hefferon, M. Kimelman, C. Liu, J. Lopez, P. Meric, C. O'Sullivan, Y. Ostapchuk, L. Phan, S. 1262 Ponomarov, V. Schneider, E. Shekhtman, K. Sirotkin, D. Slotta, H. Zhang, G. A. McVean, R. M. Durbin, S. 1263 Balasubramaniam, J. Burton, P. Danecek, T. M. Keane, A. Kolb-Kokocinski, S. McCarthy, J. Stalker, M. Quail, J. P. 1264 Schmidt, C. J. Davies, J. Gollub, T. Webster, B. Wong, Y. Zhan, A. Auton, C. L. Campbell, Y. Kong, A. Marcketta, 1265 R. A. Gibbs, F. Yu, L. Antunes, M. Bainbridge, D. Muzny, A. Sabo, Z. Huang, J. Wang, L. J. M. Coin, L. Fang, X. 1266 Guo, X. Jin, G. Li, Q. Li, Y. Li, Z. Li, H. Lin, B. Liu, R. Luo, H. Shao, Y. Xie, C. Ye, C. Yu, F. Zhang, H. Zheng, H. 1267 Zhu, C. Alkan, E. Dal, F. Kahveci, G. T. Marth, E. P. Garrison, D. Kural, W.-P. Lee, W. Fung Leong, M. Stromberg, 1268 A. N. Ward, J. Wu, M. Zhang, M. J. Daly, M. A. DePristo, R. E. Handsaker, D. M. Altshuler, E. Banks, G. Bhatia, G. 1269 del Angel, S. B. Gabriel, G. Genovese, N. Gupta, H. Li, S. Kashin, E. S. Lander, S. A. McCarroll, J. C. Nemesh, R. 1270 E. Poplin, S. C. Yoon, J. Lihm, V. Makarov, A. G. Clark, S. Gottipati, A. Keinan, J. L. Rodriguez-Flores, J. O. 1271 Korbel, T. Rausch, M. H. Fritz, A. M. Stütz, P. Flicek, K. Beal, L. Clarke, A. Datta, J. Herrero, W. M. McLaren, G. 1272 R. S. Ritchie, R. E. Smith, D. Zerbino, X. Zheng-Bradley, P. C. Sabeti, I. Shlyakhter, S. F. Schaffner, J. Vitti, D. N. 1273 Cooper, E. V. Ball, P. D. Stenson, D. R. Bentley, B. Barnes, M. Bauer, R. Keira Cheetham, A. Cox, M. Eberle, S. Humphray, S. Kahn, L. Murray, J. Peden, R. Shaw, E. E. Kenny, M. A. Batzer, M. K. Konkel, J. A. Walker, D. G. 1274 1275 MacArthur, M. Lek, R. Sudbrak, V. S. Amstislavskiy, R. Herwig, E. R. Mardis, L. Ding, D. C. Koboldt, D. Larson, 1276 K. Ye. S. Gravel, The 1000 Genomes Project Consortium, Corresponding authors, Steering committee, Production 1277 group, Baylor College of Medicine, BGI-Shenzhen, Broad Institute of MIT and Harvard, Coriell Institute for Medical 1278 Research, E. B. I. European Molecular Biology Laboratory, Illumina, Max Planck Institute for Molecular Genetics, 1279 McDonnell Genome Institute at Washington University, US National Institutes of Health, University of Oxford, W. 1280 T. S. Institute, Analysis group, Affymetrix, Albert Einstein College of Medicine, Bilkent University, Boston College, 1281 Cold Spring Harbor Laboratory, Cornell University, European Molecular Biology Laboratory, Harvard University, 1282 Human Gene Mutation Database, Icahn School of Medicine at Mount Sinai, Louisiana State University, 1283 Massachusetts General Hospital, McGill University, N. National Eye Institute, A global reference for human genetic 1284 variation. Nature 526, 68-74 (2015). 1285 96. S. A. Lambert, L. Gil, S. Jupp, S. C. Ritchie, Y. Xu, A. Buniello, A. McMahon, G. Abraham, M. Chapman, 1286 H. Parkinson, J. Danesh, J. A. L. MacArthur, M. Inouye, The Polygenic Score Catalog as an open database for 1287 reproducibility and systematic evaluation. Nat Genet 53, 420–425 (2021). 1288 97. D. Lai, E. C. Johnson, S. Colbert, G. Pandey, G. Chan, L. Bauer, M. W. Francis, V. Hesselbrock, C. 1289 Kamarajan, J. Kramer, W. Kuang, S. Kuo, S. Kuperman, Y. Liu, V. McCutcheon, Z. Pang, M. H. Plawecki, M. 1290 Schuckit, J. Tischfield, L. Wetherill, Y. Zang, H. J. Edenberg, B. Porjesz, A. Agrawal, T. Foroud, Evaluating risk for 1291 alcohol use disorder: Polygenic risk scores and family history. Alcoholism: Clinical and Experimental Research 46, 1292 374-383 (2022). 1293 98. C. T. Butts, Yacca: Yet Another Canonical Correlation Analysis Package (2022; https://CRAN.R-1294 project.org/package=vacca). G. Molenberghs, G. Verbeke, Likelihood Ratio, Score, and Wald Tests in a Constrained Parameter Space. 1295 99. 1296 The American Statistician 61, 22–27 (2007).

1297 Typendary 95, 12–64 (2024). 1301 Acknowledgments 1303 The authors gratefully acknowledge the computing time granted by the JARA 1304 The authors gratefully acknowledge the computing nart of the supercomputer JURECA and the joint lab Supercomputing and Modeling for the Human Brain at Forschungszentrum Jülich. 1307 Forschungsing grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) 1318 Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) 1319 Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) 1311 Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) 1312 Author contributions: 1313 Conceptualization: SP, SE, JW, KO, KP 1314 Conceptualization: SP, KO, KP 1315 Methodology: SP, KO, KP 1316 Investigation: SP, KO, KP 1317 Visualization: SP 1318 Supervision: KO, KP 1320 Writing—original draft: SP, KO, KP 1321 Competing interests: Authors declare that they have no competing interests. 1321 Data and materials availability: The primary data used in this study is from the UK 1322 Data and material ransfer agreement. Requests for the data should be submitted to t	1297 1298 1299	100. M. S. Mufford, D. van der Meer, T. Kaufmann, O. Frei, R. Ramesar, P. M. Thompson, N. Jahanshad, R. A. Morey, O. A. Andreassen, D. J. Stein, S. Dalvie, The Genetic Architecture of Amygdala Nuclei. <i>Biological Psychiatry</i> 95 , 72, 84 (2024)
Acknowledgments Acknowledgments The authors gratefully acknowledge the computing time granted by the JARA Vergabegremium and provided on the JARA Partition part of the supercomputer JURECA and the joint lab Supercomputing and Modeling for the Human Brain at Forschungszentrum Jülich. Funding: Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Halmoltz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Halmoltz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Halmoltz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Author contributions: Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Methodology: SP, KO, KP Writing—original draft: SP, KO, KP Writing—original draft: SP, KO, KP Writing—original draft: SP, KO, KP Data and materials availability: The primary data used in this study is from the UK Biobank: These data can be provided by UK Biobank pacing scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: and Methods. Other publicly available data sources and applications are cited in Materials and Metho	1299	<i>r sychiatry</i> 75 , 72–64 (2024).
Acknowledgments 1303 The authors gratefully acknowledge the computing time granted by the JARA 1304 The authors gratefully acknowledge the computing part of the supercomputer JURECA 1305 Vergabegremium and provided on the JARA Partition part of the supercomputer JURECA 1306 and the joint lab Supercomputing and Modeling for the Human Brain at 1307 Forschungszentrum Jülich. 1308 Funding: 1310 Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) 1311 Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) 1312 Author contributions: 1313 Author contributions: 1314 Conceptualization: SP, SE, JW, KO, KP 1315 Methodology: SP, KO, KP 1316 Investigation: SP, KO, KP 1317 Visualization: SP, KO, KP 1320 Writing—original draft: SP, KO, KP 1321 Competing interests: Authors declare that they have no competing interests. 1322 Competing interests: Authors declare that they have no competing interests. 1323 Data and materials availability: The primary data used in this study is from the UK 1326 Biobank, These data can be provided by UK Biobank data fie	1301	
The authors gratefully acknowledge the computing time granted by the JARA Vergabegremium and provided on the JARA Partition part of the supercomputer JURECA and the joint lab Supercomputing and Modeling for the Human Brain at Forschungszentrum Jülich. Bild Funding: Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Hain Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Investigation: SP, KO, KP Writing—original draft: SP, KO, KP UK Biobank: These data can be provided by UK Biobank pending scientific review and a completed materials availability: The primary data used in this study is from the UK Biobank: These data can be provided by UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https:/	1302	Acknowledgments
The authors gratefully acknowledge the computing time granted by the JARA Wergabegremium and provided on the JARA Partition part of the supercomputer JURECA and the joint lab Supercomputing and Modeling for the Human Brain at Forschungszentrum Jülich. Image: Image: <t< td=""><td>1302</td><td>Acknow reagancies</td></t<>	1302	Acknow reagancies
 Vergabegremium and provided on the JARA Partition part of the supercomputer JURECA and the joint lab Supercomputing and Modeling for the Human Brain at Forschungszentrum Jülich. Funding: Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Author contributions: Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Investigation: SP, KO, KP Writing—original draft: SP, KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Data and materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online Within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-MI/BrainPrint), MOSTest 	1304	The authors gratefully acknowledge the computing time granted by the JARA
 and the joint lab Supercomputing and Modeling for the Human Brain at Forschungszentrum Jülich. Funding: Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Author contributions: Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Bibbank. These data can be provided by UK Biobank pending scientific review and a completed materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA results within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-M//BrainPrint), MOSTest 	1305	Vergabegremium and provided on the JARA Partition part of the supercomputer JURECA
 Forschungszentrum Jülich. Forschungszentrum Jülich. Funding: Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Author contributions: Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Supervision: KO, KP Writing—original draft: SP, KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Competing interests: Authors declare that they have no competing interests. Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https://cbi.ac.uk/gwas/. We will further publish the FUMA results within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-MI/RainPrint), MOSTest 	1306	and the joint lab Supercomputing and Modeling for the Human Brain at
1308 Funding: 1309 Funding: 1310 Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) 1311 Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) 1312 Author contributions: 1313 Author contributions: 1314 Conceptualization: SP, SE, JW, KO, KP 1315 Methodology: SP, KO, KP 1316 Investigation: SP, KO, KP 1317 Visualization: SP 1318 Supervision: KO, KP 1319 Writing—original draft: SP, KO, KP 1320 Writing—review & editing: SP, FH, FR, SE, JW, KO, KP 1321 Competing interests: Authors declare that they have no competing interests. 1322 Data and materials availability: The primary data used in this study is from the UK 1325 Biobank. These data can be provided by UK Biobank pending scientific review and a 1326 completed material transfer agreement. Requests for the data should be submitted to the 1327 UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in 138 Materials and Methods. Other publicly available data sources and applications are cited in 1328 Materials and Methods. We will make our MOSTest	1307	Forschungszentrum Jülich.
1309Funding:1310Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP)1311Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP)131213131313Author contributions:1314Conceptualization: SP, SE, JW, KO, KP1315Methodology: SP, KO, KP1316Investigation: SP, KO, KP1317Visualization: SP1318Supervision: KO, KP1319Writing—original draft: SP, KO, KP1320Writing—review & editing: SP, FH, FR, SE, JW, KO, KP132113221322Competing interests: Authors declare that they have no competing interests.132313241324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1338Materials and Methods. Other publicly available data sources and applications are cited in134materials and Methods. We will make our MOSTest summary statistics available online1350within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA1351results within the FUMA database.1352This study used openly available software and codes, specifically BrainPrint1353(https://github.com/Deep-Mi/BrainPrint), MOSTest1354Other will be on/preciped/mostept.	1308	č
 Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP) Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Author contributions: Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Investigation: SP Supervision: KO, KP Writing—original draft: SP, KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Competing interests: Authors declare that they have no competing interests. Data and materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https://cbi.ac.uk/gwas/. We will further publish the FUMA results within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-Mi/BrainPrint), MOSTest 	1309	Funding:
 Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP) Author contributions: Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Supervision: KO, KP Supervision: KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Competing interests: Authors declare that they have no competing interests. Data and materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA results within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-MI/BrainPrint), MOSTest 	1310	Helmholtz Imaging grant (NimRLS, ZT-I-PF-4-010) (SP, FR, SE, KO, KP)
1312 Author contributions: 1313 Author contributions: 1314 Conceptualization: SP, SE, JW, KO, KP 1315 Methodology: SP, KO, KP 1316 Investigation: SP, KO, KP 1317 Visualization: SP 1318 Supervision: KO, KP 1319 Writing—original draft: SP, KO, KP 1320 Writing—review & editing: SP, FH, FR, SE, JW, KO, KP 1321 Competing interests: Authors declare that they have no competing interests. 1323 Data and materials availability: The primary data used in this study is from the UK 1324 Data and materials availability: The primary data used in this study is from the UK 1325 Biobank. These data can be provided by UK Biobank pending scientific review and a 1326 completed material transfer agreement. Requests for the data should be submitted to the 1327 UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in 1328 Materials and Methods. Other publicly available data sources and applications are cited in 1329 Materials and Methods. We will make our MOSTest summary statistics available online 1330 within the FUMA database. 1331 results within the FUMA database. <td< td=""><td>1311</td><td>Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP)</td></td<>	1311	Helmholtz Imaging grant (BrainShapes, ZT-I-PF-4-062) (SP, FR, SE, KO, KP)
1313 Author contributions: 1314 Conceptualization: SP, SE, JW, KO, KP 1315 Methodology: SP, KO, KP 1316 Investigation: SP, KO, KP 1317 Visualization: SP 1318 Supervision: KO, KP 1319 Writing—original draft: SP, KO, KP 1320 Writing—review & editing: SP, FH, FR, SE, JW, KO, KP 1321 Investigation: KO, KP 1322 Competing interests: Authors declare that they have no competing interests. 1323 Data and materials availability: The primary data used in this study is from the UK 1325 Biobank. These data can be provided by UK Biobank pending scientific review and a 1326 completed material transfer agreement. Requests for the data should be submitted to the 1327 UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in 1328 Materials and Methods. Other publicly available data sources and applications are cited in 1329 Materials and Methods. We will make our MOSTest summary statistics available online 1330 within the FUMA database. 1331 results within the FUMA database. 1332 This study used openly available software and codes, specifically BrainPrint 1333 </td <td>1312</td> <td></td>	1312	
 Conceptualization: SP, SE, JW, KO, KP Methodology: SP, KO, KP Investigation: SP, KO, KP Investigation: SP Supervision: KO, KP Writing—original draft: SP, KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Competing interests: Authors declare that they have no competing interests. Data and materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-MI/BrainPrint), MOSTest 	1313	Author contributions:
1315Methodology: SP, KO, KP1316Investigation: SP, KO, KP1317Visualization: SP1318Supervision: KO, KP1319Writing—original draft: SP, KO, KP1320Writing—review & editing: SP, FH, FR, SE, JW, KO, KP132113221322Competing interests: Authors declare that they have no competing interests.132313241324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/Deep-MI/BrainPrint), FUMA (https://fuma.attala.pl/	1314	Conceptualization: SP, SE, JW, KO, KP
1316Investigation: SP, KO, KP1317Visualization: SP1318Supervision: KO, KP1319Writing—original draft: SP, KO, KP1320Writing—review & editing: SP, FH, FR, SE, JW, KO, KP132113221322Competing interests: Authors declare that they have no competing interests.132313241324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/Deep-MI/BrainPrint), FUMA (https://fuma.ctalab.nl/) MAGMA	1315	Methodology: SP, KO, KP
 Visualization: SP Supervision: KO, KP Writing—original draft: SP, KO, KP Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Competing interests: Authors declare that they have no competing interests. Data and materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA results within the FUMA database. This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-MI/BrainPrint), MOSTest 	1316	Investigation: SP, KO, KP
1318Supervision: KO, KP1319Writing—original draft: SP, KO, KP1320Writing—review & editing: SP, FH, FR, SE, JW, KO, KP132113221322Competing interests: Authors declare that they have no competing interests.132313241324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the FUMA database.1331This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/Deep-MI/BrainPrint), FUMA (https://fume.ctaleh.pl/). MACMA	1317	Visualization: SP
1319Writing—original draft: SP, KO, KP1320Writing—review & editing: SP, FH, FR, SE, JW, KO, KP132113221322Competing interests: Authors declare that they have no competing interests.132313241324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/Deep-MI/BrainPrint), FUMA (https://github.com/Deep-MI/BrainPrint)	1318	Supervision: KO, KP
 Writing—review & editing: SP, FH, FR, SE, JW, KO, KP Competing interests: Authors declare that they have no competing interests. Data and materials availability: The primary data used in this study is from the UK Biobank. These data can be provided by UK Biobank pending scientific review and a completed material transfer agreement. Requests for the data should be submitted to the UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in Materials and Methods. Other publicly available data sources and applications are cited in Materials and Methods. We will make our MOSTest summary statistics available online within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA This study used openly available software and codes, specifically BrainPrint (https://github.com/Deep-MI/BrainPrint), MOSTest (https://github.com/Deep-MI/BrainPrint), FUMA (htttps://github.com/Deep-MI/BrainPrint), FUMA (<a "="" ebi.ac.uk="" gwas="" href="https:/</td><td>1319</td><td>Writing—original draft: SP, KO, KP</td></tr><tr><td>13211322Competing interests: Authors declare that they have no competing interests.1323Data and materials availability: The primary data used in this study is from the UK1324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/Deep-MI/BrainPrint), FUMA (https://fume.ctglab.pl/). MAGMA</td><td>1320</td><td>Writing—review & editing: SP, FH, FR, SE, JW, KO, KP</td></tr><tr><td>1322Competing interests: Authors declare that they have no competing interests.132313241325132513261326132613271328132913291328132913291329132913201320132113221323132413251326132713281329132913201330133113311332133213331333133413341334</td><td>1321</td><td></td></tr><tr><td>13231324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk.1328Specific UK Biobank data field codes are given in1329Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/. We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/Deep-MI/BrainPrint)	1322	Competing interests: Authors declare that they have no competing interests.
1324Data and materials availability: The primary data used in this study is from the UK1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/ . We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://fume.ctglab.pl/ MACMA	1323	
1325Biobank. These data can be provided by UK Biobank pending scientific review and a1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk.1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/ . We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://github.com/precimed/mostest)	1324	Data and materials availability: The primary data used in this study is from the UK
1326completed material transfer agreement. Requests for the data should be submitted to the1327UK Biobank: www.ukbiobank.ac.uk. Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/ . We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://fume.ctglab.pl/ MACMA	1325	Biobank. These data can be provided by UK Biobank pending scientific review and a
1327UK Biobank: www.ukbiobank.ac.uk.Specific UK Biobank data field codes are given in1328Materials and Methods. Other publicly available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/ . We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://fume.ctglab.pl/ . MACMA	1326	completed material transfer agreement. Requests for the data should be submitted to the
1328Materials and Methods. Other publicity available data sources and applications are cited in1329Materials and Methods. We will make our MOSTest summary statistics available online1330within the GWAS catalog: https://ebi.ac.uk/gwas/ . We will further publish the FUMA1331results within the FUMA database.1332This study used openly available software and codes, specifically BrainPrint1333(https://github.com/Deep-MI/BrainPrint), MOSTest1334(https://fume.ctglab.pl/ . MACMA	1327	UK Biobank: <u>www.ukbiobank.ac.uk</u> . Specific UK Biobank data field codes are given in
1329 Materials and Methods. We will make our MOS lest summary statistics available online 1330 within the GWAS catalog: <u>https://ebi.ac.uk/gwas/</u> . We will further publish the FUMA 1331 results within the FUMA database. 1332 This study used openly available software and codes, specifically BrainPrint 1333 (<u>https://github.com/Deep-MI/BrainPrint</u>), MOSTest 1334 (<u>https://github.com/Deep-MI/BrainPrint</u>)	1328	Materials and Methods. Other publicly available data sources and applications are cited in
 within the GWAS catalog: <u>https://ebi.ac.uk/gwas/</u>. we will further publish the FOMA results within the FUMA database. This study used openly available software and codes, specifically BrainPrint (<u>https://github.com/Deep-MI/BrainPrint</u>), MOSTest (<u>https://github.com/precimed/mostest</u>). FUMA (<u>https://fuma.ctglab.pl/)</u> MACMA 	1329	Materials and Methods. We will make our MOS lest summary statistics available online
 results within the FOWA database. This study used openly available software and codes, specifically BrainPrint (<u>https://github.com/Deep-MI/BrainPrint</u>), MOSTest (<u>https://github.com/precimed/mostest</u>), FUMA (<u>https://fuma.ctglab.pl/)</u>, MACMA 	1330	within the GWAS catalog: <u>https://ebi.ac.uk/gwas/</u> . we will further publish the FUMA
1332 This study used openly available software and codes, specifically BrainFlint 1333 (<u>https://github.com/Deep-MI/BrainPrint</u>), MOSTest 1334 (<u>https://github.com/precimed/mostest</u>), FUMA (<u>https://fuma.ctglab.pl/)</u> , MACMA	1331	This study used evenly evenlet a software and codes, specifically PrainPrint
1334 (https://github.com/precimed/mostest) FUMA (https://fuma.ctglab.pl/) MACMA	1332	(https://github.com/Deep_MI/ProinPrint) MOSTest
	1224	(https://github.com/precimed/mostest) EUMA (https://fuma.ctglab.pl/) MAGMA
1335 (https://gtmub.com/precimed/mostest), FOWA (<u>https://tuma.etgiab.m/</u>), WAOWA	1334	(https://cta.cncr.nl/software/magma_also implemented in FUMA) SCORE
1336 (https://cig.chci.nl/software/magina, also implemented in FOWA), SCORE	1335	(https://github.com/spiramlab/SCORE) fastman (https://github.com/kaustubhad/fastman)
1337 gasea3d (https://github.com/gaseg/gaseg3d/) circlize	1337	gasea3d (https://github.com/gaseg/gaseg3d/) circlize
1338 (https://github.com/jokergoo/circlize) and vacca (https://gran r-	1338	(https://github.com/jokergoo/circlize) and vacea (https://gran r-
1339 project org/web/packages/yacca/) We further used Affinity Designer for figure design	1339	project org/web/packages/vacca/) We further used Affinity Designer for figure design
1340	1340	